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The proteins SMYD2 and SMYD3 are two of five members of a unique family of 
lysine methyltransferases defined by a catalytic SET domain that is split into two 
segments by a MYND protein interaction domain, followed by a cysteine-rich post-SET 
domain. The SMYD family members have been shown to be essential for cellular 
development, cell cycle progression, and when dysregulated, tumorigenesis. SMYD1 has 
been widely studied as a pivotal component of cardiac and skeletal muscle development. 
Although their three dimensional structures have been solved, less is known about 
functional consequences of SMYD2 and SMYD3.  Aberrant overexpression of SMYDs 2 
and 3 have been implicated in numerous malignancies, and both have been studied as 
potential therapeutic targets.  
The overriding aim of our research is to obtain a more thorough understanding of 
SMYD2 and SMYD3 function. In Chapters 1 and 2, we outline essential background 
regarding the SMYD family and the methods used in our studies. In Chapter 3, we 
address the consequences of the interaction of SMYD3 with the nuclear chaperone, 
HSP90. Each have been independently implicated as proto-oncogenes in several human 
malignancies. Loss of SMYD3-HSP90 interaction leads to SMYD3 mislocalization within 
the nucleus, thereby severing its association with chromatin. This results in reduction of 




oncogenic activity. We suggest a novel approach for blocking HSP90-driven malignancy 
which may have reduced toxicity over current HSP90 inhibitors.  
In Chapter 4, we turn our attention to SMYD2 and its putative role in hematopoietic 
carcinogenesis. In order to study the effect of SMYD2 in tumor initiation, we employed 
transforming oncogenes to study the consequences of SMYD2 loss in three 
hematopoietic models: B-Acute Lymphocytic Leukemia (B-ALL), Chronic Myeloid 
Leukemia (CML), and Mixed Lineage Leukemia (MLL). Loss of SMYD2 in CML and MLL, 
but not in B-ALL, models led to cell cycle block following by widespread apoptosis and 
cell death. Tumorigenicity, as assessed in vitro by colony formation and in vivo by 
NOD/SCID transformation, was dependent upon SMYD2. Gene expression analyses 
indicated that, as previously determined in multiple studies, impairment included 
reduction in the level of the p53 tumor suppressor. Collectively, these studies establish 
SMYD2 as a putative proto-oncogene in CML and MLL.  
In Chapter 5, we report our efforts to extend the above findings to the living 
organism. SMYD2 was conditionally deleted via cre/Lox methodology from the germline 
of C57BL.6 mice exclusively in hematopoietic progenitors. SMYD2-deficient mice were 
born healthy and achieved normal lifespans. However, consistent with our findings of 
Chapter 4, we observed significant blocks in the progression of fetal and bone marrow 
hematopoietic stem cells to both B lymphocyte and myeloid lineages. While these blocks 
led to an overall reduction of mature peripheral B cells, SMYD2-deficient mice maintained 
a relatively normal immune response. These studies further support a model in which 
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A. SMYD FAMILY PROTEINS TARGET HISTONES AS A SUBSTRATE 
Histones play a key role in compacting meters’ worth of DNA into microscopic cells. 
The higher orders of DNA compaction are achieved by wrapping it around an octamer of 
core histones into a structural unit known as a nucleosome [1-3]. Each nucleosome 
consists of 146 base pairs of DNA wrapped 1.7 times around a histone octamer and 
separated by a linker region of approximately 50 base pairs of DNA (Figure 1) [4]. Each 
primary histone core is composed of eight histone subunits; two each of H2A, H2B, H3 
and H4. This nucleoprotein, while highly conserved in eukaryotes, is able to form a 
complex not through shared sequence homology but instead through the shared domain 
structures of the histone components which allow interactions that ultimately form the 
histone octamer [5, 6]. Two heterodimers each of H3-H4 and H2A-H2B interact with each 
other via helical folding that not only assemble the positively charged histone core but 
also establish the wrapping and tight binding of the negatively charged phosphodiester 
backbone of DNA [4].   
In addition to the folded octamer core, histones also possess unstructured N- and C-
terminal tail regions which account for approximately 28% of the histone proteins’ mass 
[7]. The tails consist of strings of amino acid residues, mostly of a basic nature. Specific 
residues can be modified in certain manners as indicated in (Figure 2). Lysine, for 
instance, can be subjected to many different post-translational covalent modifications, 
however each is mutually exclusive to another (Table 1).  It has been proposed that a 




particular action such as transcriptional activation or repression (Figure 3) [8-12]. This in 
turn provides an extension of variations in gene expression without changing the DNA 
sequence. Therefore, histones prove to be crucial to the study of altered gene expression 
and epigenetics, factors in the development of cancer cells and various disease states [9, 
13-16]. 
 
Histone modifiers and types of modifications 
 Histone modifiers, often referred to as “writers” such as methyltransferases and 
acetyltransferases, alter the nucleosomal conformation and therefore access to DNA for 
transcriptional activity [17]. Histone acetyltransferases or HATs, first discovered in 
Tetrahymena thermophile, catalytically add acetyl groups to the N-terminus of lysine (K) 
residues on histone tails utilizing acetyl CoA as an acetyl donor [18]. The activity of these 
primarily nuclear bound enzymes, is thought to neutralize a portion of the positively 
charged histone core changing its affinity to the negative DNA [19]. Due to this DNA 
disassociation and therefore access to it and the presence of HATs in some transcription 
complexes, HATs are generally associated with transcriptional activation [20]. Gene 
expression however is highly regulated and additional histone modifiers known as 
“erasers” can remove or reverse the action of a “writer”. Histone deacetylases (HDACs) 
catalytically remove the acetyl group from lysine residue thereby restoring its strong 
interaction with DNA, allowing for chromatin compaction and thereby repressing 
transcriptional activity [21, 22]     
 Unlike HATs, histone lysine methyltransferases (HKMTs) are “writers” that are 




an abundant co-substrate, S-adenosyl methionine (SAM), as a methyl donor to catalyze 
the addition of one, monomethylation (me), two, dimethylation (me2) or three, 
trimethylation (me3) methyl groups to a specific histone lysine residue [24]. Methylation 
while often pigeonholed as a gene silencing mark, can result in either activation or 
repression [25]. Certain modifications have been linked to specific outcomes, such as 
methylation of histone 3 lysine 4 (H3-K4) and H3-K36 correlating to gene transcription 
while methylation of H3-K9 and H3-K7 are correlated to gene silencing [26, 27]. Unlike 
the readily interchanging states of lysine acetylation via HATs and HDACs, most 
methylation marks are thought to have a more permanent nature. However, there is some 
turnover of histone methylation thought to be attributed to a demethylase. Lysine specific 
demethylase 1 (LSD1) is thought to function as an “eraser” of methyl marks at specific 
residues such as H3-K4 and act as a transcriptional co-repressor [28]. This dynamic 
process of “writing” and “erasing” marks on histone tail residues provides another layer 
of governing gene expression and therefore contribute to the processes of cellular 
development and disease states [10, 14, 29]. 
 
B. INTRODUCTION TO THE SMYD FAMILY PROTEINS 
There are three classes of methyltransferases (MTs). The first, called suppressor 
of variegation, enhancer of zeste and trithorax, (SET) domain lysine methyltransferases 
were originally discovered in Drosophila melanogaster [30]. The second are non-SET-
domain lysine methyltransferases and the third class are arginine methyltransferases [27, 
31]. Regardless of their classification, these “writers” orchestrate the dynamic access and 




The unique structural assembly of the catalytically active SET-domain containing 
proteins is shared throughout eukaryotes and different from that of other enzymes that 
utilize the co-factor S-adenosyl-L-methionine (SAM) as a methyl donor [31]. The distinct 
configuration of the SAM binding pocket in SET methyltransferases causes SAM to bend 
when bound to the active site. SET-containing proteins are crucial in various biological 
processes including developmental regulation, signaling cascades, association to 
chaperone proteins, and proteasomal degradation to name a few [33, 34].  
Due to several variations within HKMTs, including the conformation of SAM when 
bound, the three classes have been further categorized into subfamilies based both on 
sequence and structural homology as well as the specific methylation of lysine residues 
[5, 11, 35]. Within the SET-domain containing HKMTs is a family of proteins knowns as 
the SMYDs named as such due to possessing both a SET and MYND (Myeloid-Nervy-
DEAF1) domain [36]. While the SET domain is the active region, catalyzing the addition 
of a methyl group to lysine residues, the MYND domain contains a zinc finger binding 
motif and is known for its role in protein-protein interaction particularly to proline rich 
regions [37, 38]. The novelty of the SMYDs continues, as in their amino acid sequence 
the MYND domain lies within the catalytically active SET domain, dividing the domain into 
pre- and posterior-SET regions (Figure 4) [39-41]. However, upon proper protein folding, 
the separated SET domains fold together to produce the active site and push the MYND 
domain outward [42]. There are five total SMYD proteins, (SMYDs 1-5) each highly 
conserved among eukaryotes and with high sequence and structural homology to each 
other. SMYDs 1-3 have been the most studied and have demonstrated important roles in 




The SMYDs as HKMTs are “writers”, placing methylation marks at site specific 
lysine residues that allow for the recruitment of chromatin remodeling complexes to alter 
the access to DNA. SMYDs 1-3 have a shared methylation target at H3-K4, a site 
associated with transcriptional activity [39, 43]. However, each SMYD has additional 
unique targets that impact other processes and while they are most well-known for 
methylating their histone methylation targets, they have also proven to methylate non-
histone proteins as well.  
For instance, SMYD1 has also shown to bind to certain HDACs, resulting in 
targeted repression. SMYD1 also binds to a muscle-specific transcription factor skNAC 
(nascent polypeptide-associated complex alpha) that is required for myofibril organization 
[43, 44]. It has been identified as a muscle specific regulator and is essential not only to 
proper heart development, but also in maintaining the size of the adult heart [45, 46]. A 
global knockout of SMYD1 in mice led to embryonic lethality by day E9.5 as ventricular 
development was severely impaired [37, 47].  In addition to cardiomyocyte and myofibril 
development, SMYD1 also plays a vital role in cardiac diseases [45, 48].  
In regard to SMYD3, in addition to its activating mark of H3-K4, in the last few 
years it has recently shown to also methylate H4-K5, a residue only thought to be 
acetylated before [49]. SMYD3 is mostly associated with triggering proliferation of cancer 
cells when overexpressed, most notably in such diseases as breast cancer [50], 
hepatocellular carcinoma [51], and cervical carcinoma [52] to name a few [53]. It is 
thought that cellular growth is promoted due to its interactions with RNA polymerase II, 
the chaperone protein HSP90 and HELZ, an RNA helicase [53, 54]. SMYD3 




genes such as the homeobox protein Nkx2.8 [55]. SMYD3 methylates its target H3-K4 
resulting in transcriptional activation that outcompetes repressive markers for Nkx2.8.  
The NKx2.8 gene has been associated with cell proliferation, tumor progression and 
metastasis [56-58]. Knock down of SMYD3 by inhibitors or RNAi has shown to inhibit cell 
growth and tumor invasion [59-62].  
Recently, SMYD2 has become an interest for therapeutic cancer targets as well 
[63]. In addition to its histone lysine methylations at H3-K4 and H3-K36me2, SMYD2 is 
thought to potentially regulate the functions of tumor suppressors through its methylation 
of p53 at K370 and retinoblastoma (RB1) at K860 [38, 64-67]. The monomethylation on 
both of these well-known guardians of the genome result in the repression of their 
functions which are to mediate apoptosis and halt cell cycle progression, respectively [65, 
68]. Developmentally, unlike SMYD1, SMYD2 is dispensable for proper heart formation 
however it may play a more prominent role in other cellular pathways [69, 70].  
 
Chaperone Proteins 
Molecular chaperones are highly conserved through all branches of life, including the 
HSP90 family [71-75]. Necessary for viability of eukaryotes, HSP90 is not required in 
bacteria [76, 77]. It functions as a homodimer that associates with co-chaperones to 
catalyze the maturation and/or activation of over 100 substrate proteins that are known 
to be involved in cell regulatory pathways [75]. These ‘client proteins’ include protein 
kinases, nuclear hormone receptors, transcription factors, and an array of other essential 




of HSP90, the precise physical effects imparted by this chaperone that serve to activate 
its substrates are still poorly understood [75]. 
The most detailed understanding of the effects of HSP90 on its client proteins has 
been gleaned from its involvement with the maturation of steroid hormone receptors. 
Steroid receptors must be maintained in a labile conformation that allows them to be 
rapidly activated in the presence of their cognate ligand[79]. Hop1/Sti1, by virtue of its 
ability to bind Hsp70 and HSP90 in tandem, facilitates the transfer of Hsp70-bound 
receptors to the open form of HSP90. The HSP90 system then induces subtle alterations 
in the conformation of the bound steroid receptor that enhances its affinity toward its 
respective ligand [80]. Protein kinases comprise the most prevalent group of HSP90 client 
proteins. The co-chaperone Cdc37 is known to interact both with protein kinases and 
HSP90, thereby delivering client kinases to the HSP90 chaperone complex [81, 82]. 
Bound to HSP90, the client kinases are stabilized and remain in a receptive but inactive 
state while awaiting appropriate signals [81]. The details of the HSP90-protein kinase 
chaperone system are still under investigation. The essential roles that HSP90 fulfills in 
the normal physiology of healthy cells are even more critical for the viability of transformed 
cells. HSP90 is absolutely essential for the stabilization/maturation of nuclear hormone 
receptors, transcription factors, and protein kinases that are commonly misregulated 
during tumorigenesis [78]. It also serves to buffer the effects of transformation by 
preventing the aggregation of aberrantly expressed proteins, whose accumulation would 
otherwise result in toxic stress signals and progression to programmed cell death [83]. As 
many of the client proteins of HSP90 are linked to growth signal pathways, HSP90 is 




Amplifying the corruptive potential of HSP90 is its ability to facilitate the evolution of 
neoplastic clones by stabilizing many of the mutated proteins that are often associated 
with cancerous lesions, including p53, bcr-Abl, and v-Src [74, 83]. For this reason, HSP90 
is thought to be especially crucial in the development of tumors that result from the 
inactivation of DNA repair pathways, in which there are extensive pools of diversely 
mutated proteins. 
 
Chaperone Proteins Enhance the Methylation Ability of the SMYDs 
 As a chaperone protein, HSP90 interacts with a vast variety of client proteins. The 
unique properties of any one protein in addition to the effect of HSP90s interaction, can 
cause a number of biological responses. Some such responses include transcriptional 
regulation, proteasomal degradation, apoptosis, cellular localization, chromatin 
remodeling, etc [84].  One way in which HSP90 is able to anchor itself to and interact with 
certain proteins is via TPR (tetratricopeptide repeat) domains on the protein that consist 
of tandem repeats of amino acids. The carboxyl terminal domain of the SMYD proteins 
highly resemble that of TRP domains and are thought to be able to anchor HSP90 as a 
result. The physical interaction has been shown to enhance the SMYD methyltransferase 
activity [63, 85].   Methylation assays indicated increased methylation of H3-K4 as well as 
other targets including chromatin remodeling complexes. [86, 87]. The interaction 
between HSP90 and the SMYDs is important as their aberrant expression and activity is 
linked to many cancers. Understanding the structure and means of interactions will better 





C. THE HEMATOPOIETIC PATHWAY 
Hematopoiesis is the process that gives rise to all of the immune system cells and 
blood components via a pluripotent hematopoietic stem cell (HSC) that can differentiate 
into various committed progenitors each able to further differentiate into one or more 
functional cell types (Figure 6). Many of the functional mature cells are short lived and 
non-dividing. Therefore, they must have a means of constant renewal. The HSC resides 
in the adult bone marrow. However, in vertebrates HSC precursors known as 
hemangioblasts are first detected during embryonic development in the yolk sac [88]. 
Early in development a small population of HSC precursors are responsible for generating 
red blood cells (RBCs) as the heart continues to develop. These RBCs play a vital role in 
oxygenating embryonic tissue as it rapidly expands and increases. Later in 
embryogenesis, the HSCs migrate to another resident area known as the aorta, gonad, 
mesonephros (AGM) before their colonization in the fetal liver. While there, there is a 
clonal expansion of HSCs in the fetal liver and eventually the fetal thymus and spleen are 
also populated (Figure 7). Upon birth and thereafter, most of the HSCs can be found and 
or harvested from the adult bone marrow [88].  
While the initial migration and journey of the HSC precursor and HSC alone is an 
intricate one, that complexity continues as the single stem cell can proceed to differentiate 
down several pathways producing over thirty different progenitors, intermediate, and 
functional cells of at least ten different lineages of cells that will circulate in the blood. 
HSCs, therefore, exist either in a state extreme proliferation or of quiescence [89]. Their 
cell cycles are highly regulated by the various complexes such as cyclin dependent 




HSC quiescence. The bone marrow itself also provides a textural stromal environment 
filtering and relaying this information to the HSC population [90-93].  
However, once undergoing cell cycling, hematopoietic stem cells rapidly proliferate 
and differentiate in response to stromal signals, which include but are not limited to fms-
like tyrosine kinase 3 (Flt3), interleukin 3 (IL-3), and IL-7 [94, 95]. Immediately 
downstream of the HSC are two early non-lineage progenitors known as the multipotent 
progenitor (MPP) and the lymphoid primed multipotent progenitor (LMPP) cells. LMPPs 
are predominantly an immediate precursor to the common lymphoid progenitors (CLPs) 
which is a decisive branching point in the pathway of differentiation towards lymphocytes 
while the other pathway branches towards the myeloid derived cells (Figure 6). The 
lymphocyte pathway contains three distinct cell types (Natural Killer cells, T cells and B 
cells) that go through a variety of immature and intermediate stages and have a rather 
linear pathway of development (Figure 8). 
Unlike the simplicity of lymphocyte lineages, the myeloid pathways are many and 
complex. The MPP can give rise to a common myeloid progenitor (CMP) in addition to 
several other committed cell precursors such as the megakaryocyte-erythroid progenitor 
(MEP) either of which lead to at least one other dedicated progenitor [96]. The crucial and 
functional cells downstream of the MEP are the megakaryocytes, erythrocytes and 
platelets. Developing from the CMP progenitors are the cells that function in the immune 
activities like pathogenesis and allergic responses and include macrophages, mast cells, 
dendritic cells and the basophil, eosinophil and neutrophil cells. While hematopoiesis is 
complex in its lineages, cells can be distinguished from one another based on their 




means to investigate precise cell populations and experiment with the impact upstream 
cells have on later functional cells.  
 
Gene expression of SMYD2 in hematopoiesis 
Microarray data representing the basal gene expression of SMYD2 throughout the 
hematopoietic pathway in mice was our initial starting point for deriving our hypotheses 
(Figure 9). In the HSC and in every lineage specific progenitor, there was a high 
expression of SMYD2. The highest expression of the early cells was in the precursors to 
the megakaryocyte-erythrocyte progenitor (pMEP), granulocyte-macrophage progenitor 
(gGMP), the common myeloid progenitor (sCMP) and in the granulocyte-macrophage-
lymphoid progenitor (GMLP). More committed progenitors such as MEP and common 
lymphoid progenitor (CLP) only showed moderate expression. From the CLP where the 
T- and B- cells arise, there was a contrasting effect. In both the committed T- and B-cells 
SMYD2 expression was still present. However, it remained constant and even increasing 
again in T-cell development whereas it became nonexistent just past the initial precursor 
B cells.    
 
SMYD2 overexpression in leukemia 
Precursor-B cell acute lymphoblastic leukemia (Pre-B-ALL) is a white blood cell 
cancer that results in an excess of lymphoblasts; malignant, immature, malfunctioning 
white blood cells that rapidly develop in the bone marrow [97]. These lymphoblasts rapidly 
out-compete other healthy hematopoietic stem cell (HSC) derived cells such as B-




functioning white blood cells and an overall imbalance of other HSC derived cells causes 
a host of systemic problems in an individual including frequent infections, muscular 
weakness, liver and spleen enlargement and shortness of breath. B-ALL is most 
commonly present in children ages one to ten and 80% of childhood leukemia is 
categorized as Pre-B- ALL. Due to its breadth of symptoms and effect on the immune 
system, ALL can be fatal if left untreated for several weeks.  
Chronic myeloid leukemia (CML) is similar to ALL in that it is also a white blood 
cell cancer however it specifically affects cells downstream of the common myeloid 
progenitor which includes erythrocytes, macrophages and dendritic cells [97] whereas 
Pre-B-ALL affects cells downstream of the common lymphoid progenitor.  In CML 
aberrant blood cells mature but do not function properly and slowly over time accumulate 
and eventually outnumber healthy cells. Because CML has a slow progression rate, 
damaging effects might not be observed for months or possibly even years. Therefore, 
this type of leukemia is most common in adults.  
Both Pre-B-ALL and CML have demonstrated to generally be coupled with various 
chromosomal translocations that can be associated with either a favorable or poor 
prognosis. Pre-B-ALL cases have shown to have at least five different possible 
translocations including the non-favorable Philadelphia chromosome. CML however is 
mostly associated only with the Philadelphia chromosome translocation as it is present in 
95% of cases.  
Microarray data indicates that SMYD2 is upregulated in both ALL and CML [98, 
99] and that SMYD2 overexpression predicts low survival in both adult and children with 




non-HSC derived cancers [101]. Based on these findings we sought to look for a potential 
developmental role of SMYD2 in the hematopoietic pathway from which all of these 
immunological cancers originate. Gene expression profiling of SMYD2 demonstrates that 
SMYD2 is highly expressed in HSCs and specifically throughout HSC lineage progenitor 
cells (Figure. 9) suggesting its potential for being a key factor in HSC derived 
malignancies including Pre-B-ALL. It has been thought that SMYD2 plays an integral part 
in DNA damage response due to its methylation targets including p53 and RB [64, 66] but 
in leukemia it may do so by directly affecting the HSC pathway.  
 
D. INVESTIGATIONAL AIMS 
Aim 1: Investigate the structural and functional relationship between HSP90 and SMYD3 
both in vitro and in vivo 
We have produced a series of SMYD3 CTD truncations and mutations and 
analyzed which residues were responsible for the binding and enhanced activity of 
HSP90. Methyltransferase assays were also used to determine which SMYD3 CTD 
regions were required to be able to methylate its substrates.  
 
Aim 2: To determine the impact SMYD2 has in specific models of hematopoietic 
malignancies 
We have generated in vitro models of three types of leukemias in which SMYD2 
can be inducibly knocked out. ALL-like cells and CML-like cells were generated from 
SMYD2flox/flox pre-B or common myeloid progenitor cells, respectively. These cells were 




SMYD2flox/flox multipotent progenitor cells transduced with MLL-GAS7 constructs as well 
as cre ER. Control and SMYD2 deleted cells were analyzed for viability, cell cycle, colony 
formation and expression of tumor suppressor and related genes. 
 
Aim 3: To understand the role of SMYD2 in hematopoietic development 
We have constructed both an embryonic (vav cre) and adult inducible (mx1 cre) 
conditional knockout of SMYD2 at the hematopoietic stem cell. Early progenitors and 
stages throughout both the myeloid and the lymphoid lineage were analyzed for changes 
in the size of cell populations via flow cytometry. Mature B cells were later analyzed for 
functional production of an antibody repertoire in both control and conditional knockout 







Figure 1: Human nucleosome. Structural representation of a human nucleosome 
showing the 146 base pairs of DNA wrapped 1.7 times around a histone octamer that 
consists of two each of H2A, H2B, H3 and H4. The positive histone subunits interact with 
each other through helical folding and with DNA via its negatively charged phosphodiester 






Figure 2. Histone tails and covalent modification. (A) A cartoon diagram of the 
unstructured histone tails protruding outward from the core nucleosome. (B) Select sites 
of post-translational modifications on the histone tails. The modifications shown include 
acetylation (green diamonds), methylation (red circles), phosphorylation (blue squares), 
and ubiquitination (orange triangle). Note that Lys 9 in the H3 tail can be either acetylated 
or methylated. (Adapted from Zhang et al. Genes Dev. 2001) [25].  
 
Table 1.  Types of amino acid modifications. A table indicating the manner in which 
various histone resides can be differentially post-translationally modified. Lysine residues 




Methylation Acetylation Phosphorylation Ubiquitination Sumoylation



































Figure 3: Sites & functions of histone methylation. Site specific methylation of histone 
tail residues are associated with one or more functions. Methylation can result in either 
transcriptional repression or activation. Select known methyltransferases responsible for 
methylating the specific residue in either human or mouse genomes are indicated on the 






Figure 4: SMYD Family homology. Both the (A) cartoon diagram overlay and (B) the 
amino acid alignment display the sequence and structural identity of the familial proteins 












Figure 5: SMYDs in murine development.  SMYDs 1-3 have demonstrated roles in 
cellular development and differentiation. The murine stages of development indicate 
where each of the first three SMYDs are expressed.  All of SMYDs 1-3 are at their highest 






Figure 6: Hematopoiesis.  A simplified version of the cells derived from a single self-
renewing hematopoietic stem cell.  Two main branches, the myeloid lineage and the 






Figure 7: Migration of progenitor HSC and HSC through resident organs in 
embryonic mouse development. Precursors to HSC’s began in the yolk sac to provide 
RBCs needed to oxygenate new tissues. Those cells migrate through the AGM to the 
fetal liver before permanent residence in the bone marrow after birth [88]. Arrows indicate 







Figure 8: Lymphocytes. Downstream of the common lymphoid progenitor are the B cell, 







Figure 9: Expression of SMYD2 throughout hematopoiesis. SMYD2 is most highly 
expressed in the HSC and in the early progenitor in both the myeloid and lymphoid 
lineages. Throughout T cell development, SMYD2 expression remains high through most 
of the maturation process whereas there is little expression beyond early B cell stages. 
The myeloid lineage has varied expression of SMYD2 in its committed progenitors and 








A. MUTAGENESIS, CLONING, AND BACTERIAL EXPRESSION  
Point mutants were generated using GeneEditor in vitro Site-Directed Mutagenesis 
System (Promega) according to manufacturer’s instructions using as template full length 
human SMYD3 cloned into Gateway pENTR vector (Invitrogen). For PCR, samples were 
heated to 94°C for 5 min, subjected to amplification for 16 cycles of 0.5 mi n at 94°C, 0.5 
min at 55°C, and 0.5 min at 68°C and extended after the last cycle at 72°C for 7 min. 
 
B. BACTERIAL PROTEIN PURIFICATION  
Polyhistidine (6xHis)-tagged SMYD3 wildtype, truncation and substitution mutants 
were shuttled using directional TOPO cloning into Gateway (Invitrogen) pET™-DEST42. 
High level expression was induced by IPTG in E. coli strains MG232 (Scarab LTM) or 
HSP90PlusTM (Expression Technologies Inc). Cells were lysed in buffer A [50 mM Tris-
HCl pH7.7, 250 mM NaCl with protease inhibitors (Roche Applied Science, Cat. #11–873-
580–001)] and centrifuged to remove cell debris. The soluble fraction was purified over 
an IMAC column charged with nickel (GE Healthcare, NJ), and eluted under native 
conditions with a step gradient of 10 mM, then 500 mM imidazole. Proteins were then 
further purified by gel filtration using a Superdex 200 column (GE Healthcare, NJ), into 
25 mM Tris-HCl pH7.6, 150 mM NaCl, and 1 mM TCEP. Protein was pooled based on 





C. HISTONE METHYL TRANSFERASE ASSAYS  
For in vitro HMTase assays, SMYD3 proteins (0.1–1 μg) +/− equivalent amt. of 
human HSP90α (Assay Designs, Ann Arbor, MI, USA, cat. no SPP-776D) were incubated 
with 1 μg of mixed histones from calf thymus (Sigma) or recombinant core histones 
(Upstate). Two μCi S-adenosyl-L–[methyl-3H] methionine (SAM; Amersham Biosciences) 
was included as a methyl donor. All reactions were carried out in 40 μl HMT reaction 
buffer (10 mM dithiothreitol, 100 mM NaCl, 4 mM MgCl2, and 50 mM Tris-HCl at pH 8.8) 
at 30°C for 3 hours. An 18% SDS-PAGE gel was used to resolve samples and 
fluorography was used to visualize isotope incorporation. Substrate loading was 
visualized by Coomassie blue staining. 
 
D. HSP90 AND GST-MEEVD BINDING ASSAYS  
Determination of apparent dissociation constants (Kd) values for wildtype or mutant 
6X-His-SMYD3 with either HSP90α or GST-MEEVD (plasmid provided by Dr. Lynne 
Regan, Yale Univ.) complex formation was carried out as follows: 1.5 μM of each purified 
6X-His-SMYD3 protein was mixed with various amounts of HSP90α or GST-MEEVD 
(0.25, 0.5, 1, 2, 4, 8, 16, and 32 μM) in 130 μl of buffer B (20 mM Tris-HCl (pH 8.0), 300 
mM NaCl, 20 mM imidazole, 5 mM β-mercaptoethanol, and 5% glycerol) in the presence 
or absence of 1 mM ATP plus 5 mM MgCl2 and incubated at 25°C for 30 min. Ni-NTA-
agarose (15 μl of a 50% slurry in buffer B, Qiagen) was added to each reaction mixture, 
and incubation was carried out at 4°C with constant shaking for 40 min. Mixtures were 
transferred to an Ultrafree- MC centrifugal filter device (UFC30HV00, Millipore) and 




pelleted at 6000 rpm for 10 s. Resin was then mixed with 10 μl of elution buffer [20 mM 
Tris-HCl (pH 8.0), 300 mM NaCl, 5 mM β-mercaptoethanol, 250 mM imidazole, and 5% 
glycerol] and incubated at room temperature for 10 min. Following centrifugation at 6000 
rpm for 1min, elution step was repeated and combined eluates were fractionated on SDS-
PAGE. For input controls, 10% of the amounts of HSP90α and GST-MEEVD used for 
binding reactions were processed identically but in the absence of 6X-His- SMYD3 
proteins. After staining with Coomassie Blue, protein amounts were quantitatively 
estimated with a densitometer (GS-800™, Bio-Rad). Ratio of densities of HSP90 or GST-
MEEVD to 6X-His-SMYD3 represents the percentage of 6X-His-SMYD3 bound. 
Concentration of 6X-His-SMYD3 /HSP90 and 6X-His-SMYD3/ GST-MEEVD complexes 
were derived from the ratio of their densities multiplied by total 6X-His-SMYD3 
concentration (1.5 μM). Concentrations of respective complexes were plotted against 
total concentrations of HSP90 or GST-MEEVD. Kd values were obtained by non-linear 
least square curve fitting using the Sigmaplot program (SSPS Inc.) using the following 
equation:  
ER = (Kd + Et + Rt) ─ √(Kd + Et + Rt)2 ─ 4 X Et + Rt)/2, where ER is the concentration 
of the 6X-His- SMYD3-HSP90 or GST-MEEVD complex; Et, total HSP90 or GST-MEEVD 
concentration; and Rt, total SMYD3 concentration. 
 
E. MAMMALIAN CELL TRANSFECTION AND WESTERN BLOTTING  
Wildtype and mutant SMYD3 cDNAs were transferred from Gateway pENTR into 
pEF-DEST51 (N-terminal V5-tagged) by TOPO cloning. NIH3T3 cells were transiently 




NP- 40, 0.5% DOC, 50 mM Tris pH 8, 0.1% SDS) containing protease inhibitors (Roche 
Molecular Biochemicals, Indianapolis, IN). Expression levels were determined by 
Western blotting. Proteins were resolved on 8–15% SDS-PAGE, transferred to 
nitrocellulose (Protran BA, Schleicher and Schuell, NH), and blocked using 5% nonfat 
milk (10g nonfat milk, 150 mM NaCl, 10 mM Tris pH 8, 0.05% Tween-20) overnight at 
4°C. Membranes were incubated with anti-SMYD3 polyclonal antibody [19] for 1 hour at 
room temperature, extensively washed, then incubated with ECL Plex Goat anti-Rabbit 
IgG-Cy5 Secondary Antibody (GE Healthcare) for 1 hour at room temperature. Blots were 
exposed and developed using ECL blot detection reagent (Amersham Pharmacia 
Biotech) according to manufacturer’s instructions. 
 
F. PROLIFERATION ASSAYS  
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 C57Bl/6 embryos 
as previously described [49]. Cells were plated at ~5 × 106/ml in RPMI (supplemented 
with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 5 
× 10−5 M β-mercaptoethanol, and 1 mM sodium pyruvate) transfected) and transfected 
by lipofection (Fugene) with ~6 ug of either SMYD3 wildtype, mutants or empty vector. 
To determine the rates of cell proliferation, transfected MEFs were plated in triplicate 1 d 
after infection at a density of 104 cells/cm2 and counted every 24 h using a Z1 Coulter 







G. CELL FRACTIONATION  
Cells were separated into cytoplasmic (C), soluble nuclear protein (NP), chromatin 
(CH), and nuclear matrix (NM) fractions as follows. Approximately 1x108 cells were 
washed twice in PBS and the pellet was resuspended in 2ml HNB buffer (500 mM 
sucrose/15 mM Tris-HCL pH 7.5/60 mM KCL/.25 mM EDTA/.125 mM EGTA/.5 mM 
spermidine). Then 1ml HNBN buffer was added dropwise (HBN buffer+ 1% NP-40) and 
incubated at 4°C for 5 minutes before centrifugation at 6,000g for 3  min at 4°C; the 
supernatant of this is the C fraction. The pellet was then resuspended in 1ml CSKT buffer 
(CSK buffer + 1% Triton-X), incubated at 4°C for 5 minutes before centrifug ation at 3,000g 
for 3 min at 4°C; the supernatant of this is the NP fraction. The pellet was then 
resuspended in 720 μl CSK buffer (10 mM Pipes pH 6.8/300 mM sucrose/3 mM MgCl2/2 
mM EGTA) and 30 μl RNase-free DNase, incubated at 37°C for 15 minutes then added 
250 μl 1M AmSO4/CSK and incubate at 4°C for 5 minutes, before centrifugation at 3,000g 
for 3 min at 4°C; the supernatant of this is the CH fraction. The pellet wa s resuspended 
in 1ml 8M Urea and centrifuged at 13,000g for 5 minutes; the supernatant is the NM 
fraction. Purity of the subfractions was assessed by western blotting with antibodies noted 
in Figure 15C as previously described [50]. 
 
H. IN VITRO HEMATOPOIETIC TUMOR MODELS 
Bone marrow was extracted from femurs of SMYD2flox/flox mice. Cells were then 
depleted of erythrocytes, cultured and selected for preB, common myeloid progenitor or 
multipotent progenitor cells for ALL, CML and MLL tumors, respectively. FACS analysis 




B220+CD19+, for CML FcyRintCD34int and for MLL, Lin-Sca1+cKit+Flt3int. These cells 
were then transduced with MSCV-based retroviral p210 bcr-Abl constructs to generate 
ALL and CML-like cells and with MLL-GAS7 constructs to generate MLL-like cells.  
To induce cre to delete SMYD2, tumor-like cells were transduced with cre-ERT2 
pyromycin construct or empty vector. After, cells were treated with tamoxifen (4OHT) to 
activate cre and subsequently delete SMYD2 alleles in B cell precursor ALL, CMP cell for 
CML and in MPP cell for MLL. Samples collected over 4 days and WB. 
 
I. COLONY FORMING UNIT ASSAY 
Either 100,000 CML or MLL cells, or 10,000 ALL cells with or without treatment 
with 4-OHT to initiate deletion of SMYD2 in vitro, were plated on a semi-solid 
methylcellulose-based medium in a colony forming unit (CFU) assay. Cells were cultured 
in a 5% CO2 incubator at 37°C. Cells were left to grow in a 3D culture for 21 days and 
the media were changed every 2 days. The CFU formation was monitored weekly.  
 
J. IN VIVO TUMORS 
           NOD-SCID mice were purchased from the Jackson Laboratory (JAX Mice & 
Services Bar Harbor, ME USA). For tumor formation, 103, 104, 105 or 106 of non-treated 
(control) cre-ERT2 (n=65) or cre-ERT2 treated with 4-OHT to initiate deletion of SMYD2 
(n= 60) cells were injected intrafemorally into 6 to 8-week old male NOD/SCID mice. 
Tumor size was measured by caliper weekly for at least 3 months or until the presence 
of a tumor diameter >17mm, tumor ulceration or bleeding, when in those cases mice were 
sacrificed earlier. For examining tumor growth and/or detecting metastasis by 




Corporation). Mice were then anesthetized using Κetamine HCl, xylazine, NaCl, 0.9% 
(GE Heathcare, UK). The in vivo bioluminescense monitoring was performed in a 
Xenogen IVIS Lumina II System (Advanced Molecular Vision, Inc.). Animals were then 
sacrificed.  
 
K. CELL VIABILITY  
CML, MLL, and ALL cells were seeded in 6-well plates and cultured for up to 60 
days. Cells were harvested at 2 day intervals to detect cells undergoing apoptosis. 
Apoptosis was detected using an Annexin V-FITC apoptosis detection kit (Keygen, 
Nanjing, China). Briefly, 2×106 cells were digested into cell suspension with EDTA-free 
trypsin and resuspended in cold binding buffer and incubated for 15 min in the dark at 
room temperature following addition of 5 μl of Annexin V-FITC and 5 μl of propidium iodide 
(PI, Keygen, Nanjing, China) solutions. Flow cytometry analysis was performed using an 
LSR II Fortessa cytometer. For 4,-6-diamidino-2-phenylindole (DAPI) staining, slides 
were incubated for 30 min at room temperature in the dark with mounting medium for 
fluorescence containing DAPI (Vectoer Laboratories, Inc., Burlingame, CA, USA). The 
cells were then observed through a fluorescence microscope. 
 
L. CLONING OF THE SMYD2 CONDITIONAL TARGETING CONSTRUCT  
To construct the SMYD2 conditional targeting construct, two genomic fragments 
were first subcloned from the C57BL/6 murine Bac clone-RPC124288J3. A 2.2kb KpnI 
fragment containing exon 1 and a KpnI fragment containing 5.2kb of intronic sequence 




was excised with KpnI, blunt ended, and ligated into the unique blunt ended SalI site of 
pDELBOY [118]. The resulting clones were screened for correct orientation and for the 
regeneration of the SalI site. Fragment 2 (2.2kb) was excised with KpnI and ligated into 
the unique KpnI site of pDELBOY containing fragment 1. This was subsequently screened 
for correct orientation. Fragment 3, containing 0.6kb upstream of exon 1, was generated 
using Platinum Pfx DNA Polymerase (Invitrogen), C57BL/6 genomic DNA as template, 
and the following primer pair:  
5’GTCGACATTGAGCTAATGTGCTTA-3’; 5’-CTCGAGGTAACACTCAACCTCTGC-3’.  
The resulting PCR product was treated with TAQ Polymerase, ligated into 
pGEMTEASY (Promega), and excised with SalI and XhoI. This product was ligated into 
the unique XhoI site of pDELBOY containing fragments 1 and 2 and subsequently 
screened for correct orientation. The completed targeting construct was linearized at the 
short arm of homology using XhoI. C57BL/6 ES cells were then transfected and selected 
with G418 and gancyclovir. Targeted ES cell colonies were screened by Southern 
hybridization analysis using probes specific for the genomic sequence external to the 
arms of homology. The 5’ Southern used a 0.8kb PCR fragment using the following primer 
pair:  
5’-GGCTGGAGTTAGAGGTGGTTATGA-3’;5’-ACAGCTCTGGGCTCGGAAATAAAG-3’.  








M. CRE-MEDIATED DELETIONS  
Mice were from a C57BL/6 (CD45.1) background. To generate the SMYD2 
conditional knockout mice, we mated cre (vav or mx1) and SMYD2flox/flox YFP+ mice. To 
activate mx1-cre in vivo, 100 μg of pIpC (Sigma-Aldrich) was injected every other day for 
5 days and samples taken at least two days after the final injection. PCR genotyping from 
tail DNA was used to confirm genetic profiles and determine mates. Fluorescent 
microscope and flow cytometry were also used to determine presence of YFP.   
Mice were bred in specific pathogen-free environment and caged in groups less 
than five. During housing, animals were cleaned twice a week. All animal protocols and 
experiments were approved by the local Institutional Animal Care and Use Committee 
(IACUC). Protocol ID AUP-2012-00169 
 
N. MOUSE TAIL DNA EXTRACTION 
A crude DNA extraction was made from 2mm mouse tail clippings dissolved in 
200ul of 1x PBND buffer. 10mg/ml Proteinase K was added to each sample and placed 
at 55° C for 3hrs to overnight. Samples were then boiled for 5 minutes and  centrifuged. 
The supernatant was then used as the DNA template in the genotyping PCR experiments.   
 
O. GENOTYPING 
A PCR master mix of reagents was made to ensure each sample of 1ul mouse tail 
DNA template received 5ul 10x PCR buffer, 1ul 10mM dNTPs, .2ul Taq polymerase, 0.5ul 








Ran at: 94°C x 5’ (94°C x 30”, 62°C x 30”, 72°C x 30”) x 35 cycles, 72°C x 7’ 
Mx1 cre:  
5’GCGGTCTGGCAGTAAAAACTATC3’; 5’GTGAAACAGCATTGCTGTCACTT3’ 
Ran at: 94° C x 2’ (94° C x 20”, 60° C x 20”, 72° C x 20”) x 35 cycles, 72° C x 2’ 
Vav cre:  
5’AGATGCCAGGACATCAGGAACCTG3’; 5’ATCAGCCACACCAGACACAGAGATC3’ 




Ran at: 94° C x 5’ (94° C x 30”, 58° C x 1’, 72° C x 1’) x 35 cycles, 72° C x 7’ 
All PCR products were analyzed via gel electrophoresis. 15ul of each sample and 
loading dye was run on a 2.0% agarose gel with the addition of ethidium bromide. 
Electrophoresis was ran at 100v for approximately 30minutes before visualization in a UV 
light box. 
 
P. FLOW CYTOMETRY 
Bone marrow from femurs, spleen, thymus and peripheral blood cells were 




suspensions were washed, strained through 70um mesh filters and counted. At least 
1.5x106 cells were aliquoted into 1.5mL Eppendorf tubes, pelleted and incubated for 
30mins at room temperature in the dark or for one hour at 4° C in the dark with a 1% 
concentration of fluorescently labeled antibody (BioLegend, BD Biosciences and 
eBiosciences) stains for each tissue type in 100ul of sterile 1x PBS buffer. Cells were 
then washed of their stains, transferred to 5ml polystyrene tubes in 2ml of sterile 1x PBS 
buffer. Arc compensation beads stained for each color used per assay were used as 
controls. Definitions of each cell population were defined as denoted in Table 2 and 
antibody conjugates are listed in Table 3. All samples and controls were collected on the 
BD Bioscience LSR II Fortessa. Analysis of flow data was conducted using FlowJo 
software.  
 
Q. CELL CULTURE 
 Cell lines were grown in appropriate media; alpha-MEM for OP9 cells, RPMI for 
primary bone marrow cells and DMEM for 293T cells without any antibiotic supplements. 
Cells were cultured at 37° C in a humidified atmosphere of 5% CO 2.  
 
R. TIMED MATINGS 
Female mice (n = 1 or 2) of 6wks old were placed in a cage overnight with a single male 
mouse. Putative pregnancy was determined by the presence of a copulation plug the 
following morning (approximately 0800), which was designated as GD0.5. Female mice 
were group-housed (n = 1 to 5 mice per cage) according to their copulation-plug status,. 




S. FETAL LIVERS 
We conducted timed matings of SMYD2 F/F Vav cre+ YFP+/+ males with a SMYD2 F/F 
YFP +/- female and harvested the embryos at day E15.5. Fetal livers were removed, 
pushed through a 70 um mesh screen to obtain a single cell suspension and red blood 
cell lysed. These cells were then labeled with fluorescently conjugated antibodies and 
analyzed by flow cytometry. 
 
T. MACS CELL SEPARATION 
Magnetic cell sorting was performed using the Milyenyi Biotec lineage depletion kit 
and according to the manufacturer’s instructions in order to separate earlier bone marrow 
progenitor cells from later lineage specific cells. The bone marrow of both control and 
experimental mice were harvested by flushing mouse femurs with MACS Buffer on ice. 
The cell suspension was then strained through 70um mesh filters, washed, counted and 
labeled with CD43 magnetic beads. The labeled cells were run through the magnetic 
fields of the MACS separator columns and the effluents collected for analysis.  
 
U. B CELL PROLIFERATION ASSAY 
The proliferation assays were conducted and adapted from the Cold Spring Harbor 
Protocol for the OP9-DL1 System, doi: 10.1101/pdb.prot5156. Early primary progenitor 
cells from 4-8 week old experimental and control mouse bone marrow, previously 
separated by MACS cell separation, were strained, washed and counted. 5x105 cells 
were plated on top of a culture of 80-90% confluent OP9 cells in alpha-MEM media with 




respectively. The co-culture was maintained for up to twenty days during which time cells 
were harvested for counting, detection of YFP, and flow cytometry analysis around days 
0, 5, 8, 12 and 16. Cells were re-plated with or without trypsin mediated passage to fresh 
confluent OP9 cultures every four to five days.  
 
V. WESTEN BLOTS  
Proteins were resolved in SDS PAGE gel at 200V for 35min and electrotransfered 
by tank method to membranes at 30V for 1hour. The blots were blocked in 5% BSA with 
TBS-T buffer for 1hour, then rinsed five times for ten minutes each with TBS-T. Blots were 
incubated with primary antibody diluted in TBS-T 1:1000 overnight, washed five times for 
ten minutes each with TBS-T, and then incubated with secondary antibody 1:1000 for 
1hour. Blots were washed five times in TBS-T before visualization on Storm Imaging 
System.  
 
W. MOUSE IMMUNIZATIONS 
Mice were SMYD2flox/flox mb1 cre+ YFP or SMYD2flox/flox mb1 cre- YFP. All mice were 
maintained on a C57BL/6 background in specific pathogen–free facilities. Mice were 
immunized with NP-KLH at a molar ratio ~17:1 (NP/KLH). Antigen was precipitated on 
alum at a concentration of 1 mg/ml and delivered by intraperitoneal (100 μg) or 
subcutaneous (50 μg) injection. Blood serum was collected at 0, 14, and 28 days after 






X. ELISA  
For measuring the levels of serum IgG isotypes, ELISA plates were coated with goat–
anti-mouse Ig(M+G+A), incubated with serially diluted sera (1:50, 1:150, 1:450, 1:1,350, 
1:4,050, 1:12,150, and 1:36,450), and developed with horseradish peroxidase (HRP)-
conjugated goat Ab specific for each mouse IgG isotype (Southern Biotechnology 
Associates). Plates were developed with HRP-conjugated goat Abs specific for mouse 
IgM and IgG isotypes and Dako TMB One-Step substrate. Antibody concentrations were 
calculated by using the linear ranges of the dilution and standard curves generated with 





Table 2. Hematopoietic population definitions. Each stage of differentiation is unique 
in its expression of extracellular surface markers. Cells were distinguished from each 





Tissue Population Population Abbr Marker Lineage
Hematopoietic stem cell HSC Lin-Sca1+ckit+Flt3- B220, CD19, CD3e, CD4, 
Multipotent progenitor MPP Lin-Sca1+ckit+Flt3int CD8a, CD11b, Gr1, NK1.1, 
Lymphoid primed multipotent progenitor LMPP Lin-Sca1+ckit+Flt3hi Ter119
Common lymphoid progenitor CLP Lin-Flt3+IL-7+Sca1low+ckitlow
Common myeloid progenitor CMP Lin-Sca1-+ckit+ FcyRintCD34int
Granulocyte/macrophage progenitor GMP Lin-Sca1-+ckit+ FcyRhiCD34hi
Megakaryocyte/erythroid progenitor MEP Lin-Sca1-+ckit+ FcyRlowCD34low
Progenitor B cell Pro-B B220+CD19-CD43+ckit+IgM-
Pre B cell  Pre-B B220+CD19+CD43-IgM-
Large Pre-B Large Pre-B B220+CD19+CD43+IgM-BP1+
Small Pre-B Small Pre-B B220+CD19+CD43-IgM-CD2+
Immature B cell Imm B B220+CD19+CD43-IgMhiIgD-
Mature B cell or Recirculating B cell Mat B or Recirc B220+CD19+IgMhiIgD+
Macrophage Macro Mac1+Gr1lowCD115+
Granulocytes Gran Mac1+Gr1hiCD115-
Plasmacytoid dendritic cell pDC CD11b-CD11clowB220+PDCA1+
Double negative DN CD4-CD8- B220, CD19, CD3e, CD8a 
Double positive DP CD4+CD8+ TCRB, TCRyΔ, CD11b, NK1.1, 
Helper T cells CD4+ CD4+CD8- Ly-6G, CD11b, CD11c,Ter119
Cytotoxic T cells CD8+ CD4-CD8+
Immature B cell Imm B B220+CD19+IgMhiIgD-
Transitional B cell 1 Trans B 1 B220+CD19+IgMhiIgD-CD21-CD23-
Transitional B cell 2 Trans B 2 B220+CD19+IgMhiIgD+CD21+CD23+
Mature B cell or Recirculating B cell Mat B or Recirc B220+CD19+IgMhiIgDhi
Follicular B cell FO B B220+CD19+CD21intCD23hi



























 Table 3. Epitopes and conjugated antibodies. Stains utilizing the listed fluorescently 
labeled antibodies were used to define cells as mentioned in Table 2. 
Epitope Conjugate Epitope Conjugate
B220 qDot605 CD71 PE
Alexa700 ckit PE-CY7
BP1 PE F4/80 PE-CY7
CD2 APC FCyR PE
CD3e APC-CY7 Flt3 APC
PerCP-CY5.5 Gr1 APC
CD4 PerCP-CY5.5 PerCP-CY5.5
CD8a APC IgD Pacific Blue
PerCP-CY5.5 IgM APC-CY7
CD8b.2 Pacific Blue PerCP-CY5.5
CD11b PE-CY7 IL-7Ra V21
Pacific Blue PerCP-CY5.5
PerCP-CY5.5 MHCII Pacific Blue
CD11c APC-CY7 NK1.1 PerCP-CY5.5
CD115 qDot605 PDCA1 PE
CD19 APC Sca1 APC-CY7
Alexa700 Alexa700
CD21/35 PE-CY7 TCRB APC
CD22 PE TCRyΔ PE







CHAPTER 3 – C-TERMINAL DOMAIN OF SMYD3 SERVES AS A UNIQUE HSP90- 




The histone code of post-translational modifications determines the level of 
chromatin accessibility to both transcription factors and polymerase complexes [11, 104, 
105]. In this way, the SMYD family of histone methyltransferases (HMTases) plays critical 
roles in the modulation of transcriptional activity to impart normal cellular differentiation 
as well as oncogenic transformation. SMYD3 catalyzes trimethylation (me3) of H4-K20 
[106], H4-K5 [49] and H3-K4 [54] and monomethylation of vascular endothelial growth 
factor receptor 1 [107]. These various histone methylation marks lead to altered 
expression levels of genes physically associated with the methylated histone. Indeed, 
SMYD3 has been strongly implicated as a proto-oncogene in hepatocellular, colorectal 
and breast carcinomas [40, 50, 108-110] by virtue of its high over-expression and 
promoter-associated polymorphisms specific to malignant cells. 
 HSP90 is a key chaperone involved in the proper folding of many cellular proteins 
and its deregulation is strongly implicated in a broad array of malignancies [78, 111]. At 
the same time, HSP90 has been implicated as a driver of evolution, either as a stabilizer 
of particular polymorphisms in coding and regulatory sequences of key proteins  [84, 112] 
or as an inducer of heritably altered chromatin states [113], suggesting it has a significant 
role in epigenetic modification. This later role is more surprising, as HSP90’s primary role 
is traditionally seen as a folding chaperone to a vast number of client proteins, including 
a myriad of epigenetic regulators. It remains an open question as to whether HSP90 has 
specific interactions with a select few epigenetic proteins through which the heritably 




HSP90 has been the target of many novel cancer therapeutics. The most advanced of 
these function by occupying the ATP binding site, thus blocking the release of HSP90 
substrates. Unfortunately, adverse side effects are the unintended consequence of 
eliminating the molecular chaperone activity of this broadly expressed and essential 
protein [114]. Altering the association of HSP90 with specific partners is seen as a 
potential, but challenging and as yet unsolved, approach toward mitigating these side 
effects. One line of thought is that altering the epigenetic functions of HSP90 without 
significantly altering its molecular chaperone function might lead to a better tolerated 
therapeutic outcome.  
SMYD3 and HSP90 can physically interact, with HSP90 stimulating the basal 
HMTase activity of SMYD3 [40]. The relevance of this association in a cellular milieu and 
its association with the epigenetic roles of either of these proteins is, however, poorly 
characterized. The potential to connect both the physical associations and the epigenetic 
functions of SMYD3 and HSP90 has increased significantly with the almost concurrent 
publication of three independent crystal complexes of SMYD3 [39, 115, 116]. The SMYD3 
structures revealed an overall compact architecture in which the N- and C-terminal 
portions of the “split-SET” domain (N-SET and C-SET) adopt a canonical SET domain 
fold and closely assemble with the MYND (Myeloid translocation protein 8, Nervy, and 
DEAF-1) zinc-binding and protein-protein interaction domain .[117-119] The structures 
also feature a previously uncharacterized, ~150 residue C-terminal domain (CTD) which 
is conserved in all SMYD paralogs except SMYD5. The CTD forms a superhelical 9 α-
helical bundle which constricts the floor of the substrate binding site to a variable degree 




appears to be a second protein-protein interaction domain, termed the tetratricopeptide 
repeat (TPR). TPRs facilitate a wide range of diverse functions and are composed of ~34 
amino acids of roughly conserved sequence that invariably assemble into characteristic 
helix-turn-helix structures [120]. A previously documented interaction of HSP90 with the 
TPR of the cyclophilin FKBP52 [121, 122] implicates the CTD as the HSP90 binding motif 
for most human SMYDs [123, 124]. This model was suggested for SMYDs 2, 3, and 5 
[85], but the cellular consequences of potential HSP90-SMYD interactions have not been 
addressed.  
Herein, we investigate the structural and functional relationship between HSP90 and 
SMYD3 both in vitro and in vivo. We show that the CTD is essential for basal SMYD3 
methyltransferase activity and establish a unique interfacial interaction for maximal 
HMTase induction by HSP90. We suggest that disruption of the association between 
SMYD3 and HSP90 may impact cellular differentiation and oncogenic transformation, 
providing a potential avenue for blocking HSP90- enabled malignancy with a reduced 
toxicity profile in SMYD3-overexpressing cells.  
 
A. RESULTS 
The CTD is required for basal HMTase activity of SMYD3 
 Inspection of the SMYD3 structure (Figure 10A) revealed that a relatively large space 
near the post-SET domain and N-terminal portion of the CTD along the inner wall of the 
pocket is decorated by polar residues from the CTD (mainly residues from N324-C333 of 
helix 4) (Figure 10B). Sirinupong et al. [125] had identified residue K329 as a key linchpin 




addition, residues T277 and N327 form multiple hydrogen bonds which help stabilize the 
assembly of helices 1–4 of the CTD. The remaining residues (E294, E295, D332, and 
C333) all align in roughly linear fashion in close succession, except for Q287. This 
conserved clustering suggests that these polar residues might cooperate with the post-
SET residues to restrict the histone substrate on both sides of the methyl-lysine. In this 
context, the CTD could function as a cap necessary to bind substrates effectively and 
selectively. Consistent with this hypothesis, deletion of CTD helices 1–9 [SMYD3(1–279)] 
eliminated basal HMTase activity of SMYD3 for histone H4 (Figure 11A).  
This loss in basal HMTase is also associated with significantly reduced binding of 
SMYD3 to HSP90 (Figure 11B). The C-terminal five residues (MEEVD) of HSP90 are 
putatively sufficient to recognize TPR motifs [122]. While this pentapeptide bound WT 
SMYD3, it failed to interact significantly with SMYD3(1–279). This indicated that not only 
is the CTD required for the basal HMTase activity of SMYD3, but that recognition of 
HSP90 via its last five C-terminal residues may also be required. Unexpectedly, deletion 
of helices 7–9 [SMYD3(1–364)], which neither contains nor interacts with any of the polar 
residues mentioned above, also led to loss of basal HMTase activity and to loss of binding 
to HSP90 and its derivative MEEVD peptide (Figure 11).  
 
Structural conservation of SMYD3 CTD and the HSP90-binding tetratricopeptide (TPR) 
repeats within FKBP52 
To reconcile the above results for SMYD3(1–364), a model of the binding of HSP90 
to the CTD of SMYD3 proved extremely helpful. The CTDs are significantly conserved 




[42, 116, 125] have posited that the CTD of various SMYDs may be associated with 
HSP90 binding and have even generated overlays predicting the orientation of the 
MEEVD peptide in the TPR-like motif. Recapitulation of this overlay (Figure 13A, 13B) 
using FKBP52, which was solved in a complex with the terminal 5 amino acids (MEEVD) 
of HSP90 [122], indicated that the overlay may be incorrect. 
 First, the HSP90 pentapeptide is inserted deep into the pocket, leading to a 
potential steric conflict between HSP90 and substrates of SMYD3. The HSP90 CTD is 
almost certainly not a disordered domain nor is it a purely linear chain. But in this model, 
the CTD must be positioned somewhere near the lip of the SMYD3 protein, thereby 
reducing access. Second, the residues in that region are incompatible with the HSP90 
peptide (Figure 13B). Several of the residues of the MEEVD peptide model are in steric 
clash with the CTD residues, where a loop from the I-SET domain occupies a similar 
space. This clash was rationalized away by hypothesizing an autoinhibitory mode [42], 
which we grant is possible. Yet, even if the SMYD3 side chains were adjusted so as to 
relieve steric clashes, the acidic residues of the HSP90 C-terminal tail sit in a neutral to 
acidic portion of the pocket, suggesting a lack of electrostatic complementarity as well. 
Third, deletion of helices 7–9 should not significantly perturb the MEEVD peptide binding 
which is inconsistent with our data (Figure 11B). Thus, an alternative binding mode must 






TPR-like residues of SMYD3 CTD are essential in vitro for HSP90 binding and catalytic 
enhancement 
In order to reconcile our data with a TPR-like motif which could bind HSP90, we 
aligned helices 7–9 with the HSP90 binding region of FKBP52 [121, 122] (Figure 13C). 
Helices 4–9 in SMYD3 align with the first 3 helices of the TPR motif from FKBP52 (Figure 
13D), which features the C-terminal pentapeptide MEEVD. Several SMYD3 residues 
between CTD helices 4 and 5, 7 and 8, and at the end of helix 9 were predicted from the 
FKBP52 structure [122] to be within contact distance (6Å) of the modeled HSP90 
pentapeptide. All are conserved among closest SMYD3 orthologs and, to varying 
degrees, among SMYD3 paralogs and with FKBP52 (Figure 12; Table 4). Mutation of 
several of these residues led to diminished SMYD3 binding to both HSP90 and MEEVD, 
including I339 and K375, structural anchors between N- and C-terminal components of 
the CTD, or to complete loss of binding on mutation of H382, a potential HSP90 interfacial 
residue, or C421, an anchor for helix 9 to the rest of the CTD (Figure 14A). Dissociation 
constant (Kd) measurements averaged from 5 biologic replicas with density 
measurements within linear range (Materials and Methods) indicated that HSP90 and 
MEEVD binding losses ranged from ~10-fold for I339A at the low end to ~40-fold for 
C421A at the high end (Table 4). The same point mutations lost up to 8-fold enhancement 
of HSP90 stimulation of HMTase activity toward histone H4 (representative data in Figure 
14B; Table 4).  
To ensure that these mutations are specific, we mutated nearby residues, such as 
N340 and E420. These mutations had no effect on HSP90 binding or enhancement 




helices of the SMYD3 CTD are required for its constitutive HMTase activity, whereas the 
TPR-like C-terminal helices are required for the enhanced activity afforded by HSP90.  
 
TPR-like residues of SMYD3 CTD are essential in vivo for nuclear localization, HSP90 
interaction and sub-nuclear sequestration into chromatin 
To establish the cellular effects of the deletion and point mutants which impaired 
HSP90 binding in vitro, nuclear (N) and cytoplasmic (C) distributions of their 
overexpressed FLAG-tagged constructs were evaluated in NIH3T3 fibroblasts. As shown 
in Figure 15A, deletion of the 9 helices of the CTD in SMYD3(1–279) eliminated nuclear 
localization (compare lanes 5 and 6), whereas deletion of helices 7–9 in SMYD3(1–364) 
(lanes 3 and 4) showed no difference with wildtype (WT, lanes 1 and 2). Thus, nuclear 
entry function resides within helices 1–6 of the CTD. Potentially relevant is the previous 
observation that the predictive general nuclear localization sequence (NLS) for Kapβ2 
transporter recognition (ΦGΦΦX13RX3 PY; Φ, any hydrophobic residue) [126] matches 
the SMYD3 sequence from L341 to Y358. This sequence and, particularly the P357Y358 
essential for Kapβ2-NLS recognition, are not exposed, but buried by helices 7–9 of the 
CTD of SMYD3, suggesting HSP90 C-terminal binding may serve to expose the putative 
NLS. 
 Next we tested whether the HSP90 binding requirements established in vitro were 
observed in cells. Following over-expression of the indicated SMYD3 constructs of Figure 
15B, ~5% of the protein was reserved for Input (lane 1) and the remainder was subjected 
to antiSMYD3 or anti-HSP90 immunoprecipitation (IP; lanes 2 and 3) with pre-immune 




interactions of over-expressed SMYD3 with endogenous levels of HSP90 were assessed 
by anti-HSP90 and anti-FLAG western blotting. Strong, reciprocal interaction was 
observed for SMYD3 WT, whereas no interaction was detectable if helices 7–9 were 
truncated [SMYD3(1–364), Figure 15B]. Each of the SYMD3 point mutants which had 
reduced or no interaction with HSP90 in vitro (Figure 14B) showed highly reduced 
interactions in NIH3T3 cells (Figure 15B).  
The lack of association between HSP90 and SMYD3 mutants raised the possibility 
that HSP90 interaction with SMYD3 CTD, and particularly helices 7–9, is essential for 
SMYD3 nuclear transport. To address this, we overexpressed select SMYD3 substitution 
mutants (Figure 15C), fractionated the NIH3T3 cells into cytoplasmic (C), soluble nuclear 
(N), chromatin (Ch) and nuclear matrix (NM) components and then carried out semi-
quantitative antiFLAG Western analysis. Established markers (bottom 3 panels) validated 
purity of the sub-fractions. As previously shown [74, 127], HSP90 accumulates in the 
cytoplasm (C) and within the soluble and chromatin sub-fractions (Figure 15C, lanes 1 
and 3). WT SMYD3 accumulated in a similar pattern as HSP90. While nuclear localization 
was achieved with SMYD3(1–364) and each of the nonHSP90 interacting point mutants, 
they were mislocated to various extents, with virtually complete loss of K375A and H382A 
from chromatin into the nuclear matrix (compare lanes 3 and 4). Hence, association of 
the SMYD3 CTD with HSP90 is not required for nuclear transport per se but is required 







CTD-HSP90 interaction is required for maximal SMYD3 stimulation of cell proliferation  
Although maximal nuclear activity of SMYD3 requires HSP90 association, its 
activity against cytoplasmic targets may be uncompromised and hence may not require 
HSP90 interaction for its oncogenicity. Numerous studies [50, 54, 128-130] demonstrated 
proto-oncogene-type actions of SMYD3 under conditions of genetic-based promoter 
mutations leading to gain-of-function in malignant tumors or following enforced ectopic 
over-expression in non-transformed cells. HSP90 assists in the folding and function of 
numerous proto-oncogenes, as its inhibition by small molecules or siRNA leads to their 
destabilization and subsequent suppression of malignancy. As shown in Figure 16, stable 
over-expression of wildtype SMYD3 in mouse embryonic fibroblasts (MEFs) leads to a 
statistically significant (p < .001) approximately 3-fold enhancement in proliferation 
relative to vector control. This enhancement is significantly abrogated to varying extents 
in SMYD3 CTD mutants impaired in HSP90 interaction. Specifically, we observed low 
statistical difference (p < 0.10) between vector-only and all CTD mutants which lose 
HSP90 association, whereas the I339A mutation which retains HSP90 association trends 
much more closely to that of WT SMYD3 (p < 0.10). We did not observe significant 
changes in morphology, adhesion or cell migration following enforced expression of 
SMYD3, as was observed in some previous reports [50, 54, 128-132] .That these 
previous enforced expression studies were performed in transformed cell lines, which 
quite probably express higher levels of endogenous SMYD3 than did our diploid MEF 







Figure 10: Structure of SMYD3.  (A) Structure of SMYD3 colored by domain 
components. SMYD3 has 6 domain components: N-SET (red), MYND (Yellow), I-SET 
(cyan), C-SET (magenta), post-SET (pale green), and the CTD (blue). (B) Cross-eye 
Stereo view of helices 1–6 of the CTD of SMYD3. SMYD3 domains are colored 
separately, with the CTD colored blue. Residues conserved in SMYD3 orthologs but not 
paralogs are displayed in thick bonds. Dashed lines indicate hydrogen bonds. Underlined 
residues are available on the surface for interactions. Other domains include the N-SET 









Figure 11: The SMYD3 CTD is required for binding and enhanced Histone Methyl 
Transferase Activity (HMTase) by HSP90. (A) Truncation mutants were expressed in 
E. coli and validated for purity on 10% SDS-PAGE stained with Coomassie Blue (Upper 
panel). Equal amounts of truncated and wildtype (WT) SMYD3 were then compared for 
in vitro HMTase activities in the presence or absence of HSP90 by 3H-S-
adenylmethionine incorporation into histone H4 (3H-H4) followed by gel fractionation and 
autoradiography after loading onto a separate 20% SDS-PAGE (lower and middle 
panels). The SMYD3(1–279) truncation eliminates the entire CTD, while SMYD3(1–364) 
lacks the final 3 helices of the CTD. Molecular weights in kD indicated to the right of each 
panel were determined from marker mix (M, included in Lane 1 with H4 only) which, as 
indicated by the blue vertical line was run on parallel 10% and 20% gels. (B) The SMYD3 
CTD is required for binding of HSP90 and for binding to a pentapeptide MEEVD 
previously shown [29] to be sufficient for the interaction of HSP90 and a TPR domain 
within the immunophilin, FKBP52. Nickel-NTA beads were mixed with ~1 μg wildtype 
(WT) 6X-His-SMYD3 or ~1 μg 6X-His-mutants in which the entire CTD (1–279) or its C-
terminal 3 helices (1–364) were truncated. The slurries were incubated with either 
HSP90α or GST-MEEVD and bound protein (B lanes) was eluted from the beads and 
analyzed on 12.5% SDS-PAGE. For input controls (I lanes), 10% of the amounts of 
HSP90α and GST-MEEVD used for binding reactions were processed identically but in 
the absence of 6X-His-SMYD3. Band assignments (left) were made by sizes of 
Coomassie stained bands (upper panel) as judged by migration of a standard molecular 
weight marker mix (not shown). These assignments were confirmed (lower panels) by 
western blotting using antibodies (indicated on the left) specific for SMYD3, HSP90 and 
GST. Arrows denote positions of WT bound HSP90 or GST-MEEVD. Molecular weights 
are indicated on the right in kD. Blue vertical lines denote composites of lanes run on 







Figure 12: Alignment of the carboxyl terminal (CTD) domain from SMYD3 orthologs 
and paralogs. Structure of the 9-helix bundle SMYD3 CTD (right upper panel, blue). The 
primary human sequence of SMYD3 CTD is aligned (lower panel) with corresponding 
CTDs of closest paralogs, SMYDs1 and 2, in multiple species. Residues are colored 
according to their physical properties. For example, all shades of red represent acidic 
residues, all shades of blue represent basic residues, and all shades of green represent 
hydrophobic residues. Black boxes in the alignment indicate residues conserved among 
orthologous SMYD subfamilies but not among paralogs in the same species. Red boxes 
below the alignments correspond to the SMYD3 residue labels in the upper right hand 
corner. These residues are modeled as being within 6Å of the MEEVD C-terminal peptide 






Figure 13: Residues within a degenerate tetratricopeptide (TPR)-like domain within 
the SMYD3 CTD mediate HSP90 interaction. (A) Cross-eye stereo recapitulation of the 
modeled overlay of SMYD3 CTD (blue) with the TPR motif from FKBP52 (yellow) as in 
[20, 21, 26]. The N-terminal of the CTD is labeled for clarity of orientation. (B) Stereo 
close-up of the overlay in Figure 13A, with ribbon coloring retained. Residues from 
SMYD3 are in green while the MEEVD pentapeptide from the C-terminus of HSP90 in the 
FKBP52-bound structure is in magenta. The residues from the I-SET domain are marked 
by the cyan ribbon. (C) Stereo depiction of the current publication’s modeled overlay of 
helices 7–9 of the SMYD3 CTD (blue) with the HSP90-binding region of FKBP52 (yellow). 
(D) Stereo close-up of the overlay in Figure 13C, with ribbon coloring retained. Residues 
from HSP90 are in black, while those from SMYD3 are in off-white. Residues in the vicinity 





Table 4: Summary of HSP90 binding and histone methyltransferase activities 
following truncation or point mutation of residues within the SMYD3 CTD. §Mutated 
residues conserved among SMYDs 1, 2, 3 and/or FKBP52 (F); #ratio of HSP90-induced- 
to basal- in vitro SMYD3 HMTase activities for the indicated construct (Methods and 
Materials). A minimal number of 4 biological replicates were measured to determine 
ratios, standard deviations, and statistical significance. Basal levels were eliminated by 
the two CTD deletions [SMYD3 (1-364) and (1-279)] but remained essentially unchanged 
for any of the point mutations listed here. **SMYD3 side chain predicted to be within 6Å 









Figure 14: Enhancement of basal HMTase activity of SMYD3 requires binding of 
HSP90 to conserved residues within a TPR-like region of the CTD. (A) Conserved 
residues within a TPR-like region of SMYD3 CTD are required for HSP90 and MEEVD 
binding. Residues mutated (detailed in Materials and Methods) were predicted to interact 
with the HSP90 peptide or to be critical for CTD integrity. Nickel-NTA beads were mixed 
with ~1 μg wildtype (WT) 6X-His-SMYD3 or ~1 μg 6X-His-mutants. The slurries were 
incubated with either HSP90α or GST-MEEVD and bound protein was eluted from the 
beads and analyzed on 12.5% SDS-PAGE. Arrows denote loss of SMYD3-mutant 
interaction. Blue vertical lines denote repositioning of lanes run on the same gel 
repositioned to emphasize outcomes. (B) CTD residues required for HSP90 binding are 
required for HSP90-mediated enhancement of SMYD3 HMTase activity. In vitro 3H-SAM 
HMTase assays (autoradiographs, center panels) were performed as described in 
Materials and Methods and in the legend to Figure 11A. Inputs are shown by Coomassie 











Figure 15: TPR residues of SMYD3 CTD are essential in vivo for nuclear 
localization, HSP90 interaction and sub-nuclear sequestration into chromatin. (A) 
Deletion of the 9 helices of the CTD eliminates nuclear localization. Upper panel: NIH3T3 
cells were transiently transfected with the indicated FLAG-tagged SMYD3 WT or deletion 
mutants, separated into nuclear (N) and cytoplasmic (C) fractions, and protein lysates 
were analyzed by SDS-PAGE/anti-FLAG western blotting. Purity of the fractions and 
confirmation of equal protein inputs was confirmed by anti-Lamin B western (lower panel). 
(B) Confirmation in vivo of SMYD3-HSP90 interactions established in vitro. Following 
transient transfection of the indicated FLAG-tagged wildtype (WT) and CTD point mutants 
into NIH3T3 cells, ~5% of the whole cell lysate was reserved for Input (lanes 1) and the 
remainder was subjected to immunoprecipitation with antibodies (α) specific for SMYD3 
or HSP90 (IP; lanes 2 and 3) with pre-immune sera (anti-Ig, lanes 4) serving as negative 
control. Complexes were resolved on SDS-PAGE, and interactions of over-expressed 
SMYD3 with endogenous levels of HSP90 were assessed by anti-HSP90 and anti-FLAG 
western blotting. (C) CTD mutation perturbs distribution of SMYD3 within sub-nuclear 




NIH3T3 cells were fractionated into cytoplasmic (C), soluble nuclear (N), chromatin (Ch) 
and nuclear matrix (NM) and following resolution on SDS-PAGE, protein subcellular 
localization was assessed by semi-quantitative anti-FLAG Western analysis. Western 







Figure 16: CTD-HSP90 interaction is required for maximal SMYD3 stimulation of 
cell proliferation rate. The indicated WT and mutant constructs (top left) were transiently 
transfected into mouse embryonic fibroblasts. Relatively equal levels of expression were 
confirmed by Western blot of total cell lysates at day 1 (inset). Proliferation rates were 
assessed at the indicated time-points following transfection by counting trypan blue-
negative (living) cells. Growth curves are shown as averages of 4 independent 
experiments with standard deviations (I) Brackets denote paired t-test-derived mean-
difference probabilities (p) with width of the bracket representing magnitude. Δ364 stands 





B. CONCLUSION  
 
SMYD3 is overexpressed in a variety of tumor types, including hepatocellular 
carcinomas and breast cancers, with poor prognosis commonly observed [41]. It is an 
important epigenetic regulator, known to methylate histones at several sites, including 
H4-K20. We demonstrate that the C-terminal domain (CTD) is essential for SMYD3’s 
histone methyltransferase (HMTase) activity, as truncates of either the whole CTD or 
even just the three C-terminal helices of the CTD suffice to eliminate basal methylation of 
H4, both in vitro and in vivo. A central hypothesis proposed in the analysis of SMYD1 as 
applied to SMYD3 [20] conflicts with our results. Based on the differential geometries 
adopted by the CTDs of SMYD1 and SMYD3, those authors speculated that the SMYD3 
CTD must undergo a hinge-like movement to relieve its inherent auto-inhibition of 
substrate entry and/or release, suggesting that the CTD serves mainly a regulatory role. 
In contrast, we directly demonstrated that CTD deletion greatly reduced enzymatic activity 
(Figure 11A and Table 4), suggesting that, at least for basal histone catalysis, the CTD 
stabilizes the SMYD3 active site.  
To further understand the binding determinants of this regulatory site, we 
hypothesized that HSP90, which is known to stimulate SMYD family HMTase activity 
upon binding, interacts with the final three helices of the CTD. This proposal stands in 
contrast to earlier predictions which suggested that the entire CTD should interact with 
HSP90, based on overlays between the CTD and the HSP90-interacting tetratricopeptide 
repeat (TPR) domain of FKBP52. Detailed analysis of the HSP90 binding site modeled 
onto SMYD3 suggested several residues important for binding. These residues are 




significance. Our data establish a strong correlation between modification of these 
terminal helices, either through truncation or through point mutations, and sensitivity to 
HSP90 activation. Most strikingly, the side chain of H384 points out into solvent and is 
not expected to play a role in SMYD3 CTD conformational integrity but is predicted in our 
model to play an important role in HSP90 C-terminal recognition. As predicted, the H384A 
substitution mutant suffers near complete loss of HSP90 activation of SMYD3 both in in 
vitro and cellular contexts, suggesting the modeled binding model is indeed predictive. 
Only the last 5 C-terminal residues of HSP90 (MEEVD) play a significant role in SMYD3 
activation, as association and activation patterns are nearly identical between the full 
length HSP90 and the 5-mer (Table 1).  
The TPR-like CTD of SMYD3 also appears necessary for cell localization and for 
nuclear trafficking. Indeed, the TPR motif has been well documented for its role in HSP90-
dependent protein localization [42]. For example, mitochondrial localization of the 
immunophilin FKBP51 is dependent upon HSP90 via the TPR motif of FKBP51 [43]. 
Without a TPR motif and/or in the absence of HSP90, FKBP51 translocates to the nucleus 
where it has been shown to prevent oxidative stress [43]. Conversely, the association of 
many nuclear hormone receptors with TPR-motif containing proteins is known to facilitate 
their transport into the nucleus via association with HSP90 complexes [42]. Such is the 
case with the mineralocorticoid receptor which is transported into the nucleus by way of 
its association with TPR-containing FKBP52 in an HSP90 complex [44].  
Our results indicate that a substantial, if not exclusive, component of SMYD3-driven 
proliferation derives from its CTD interaction with HSP90. HSP90 facilitates SMYD3 




cannot exclude HSP90 catalyzed stabilization of SMYD3 as the primary driver of the 
proliferation results, the fact that MEEVD suffices to activate SMYD3 in vitro but is not 
considered relevant to HSP90’s chaperone function suggests HSP90 most likely serves 
to relieve the regulatory components on SMYD3 to enable SMYD3’s epigenetic function. 
Nevertheless, sorting out the relative importance of these multiple HSP90 interaction with 
SMYD3 in native and oncogenic environments warrants further exploration. Based, then, 
on our data, a model of SMYD3- HSP90 cooperatively in heritably altering chromatin 
states emerges, with HSP90 interactions with the CTD of SMYD3 proceeding via a two-
component regulatory motif. The terminal helices 7–9 in this motif serve as a regulator of 
both the nuclear localization and compartmentalization sequences, with regulation of the 
latter facilitated through the enhanced accessibility of histone substrates. Relief of this 
HSP90-dependent regulatory feature permits a conformation in SMYD3 that supports 
efficient substrate binding. The remainder of the CTD (helices 1–6) serves as a binding 
enhancer and specificity determinant for SMYD3 substrates. Increasing levels of SMYD3 
in the presence of HSP90 effectively allows HSP90 to transform into an epigenetic agent.  
Given the general nature of HSP90 as a stress sensor, the connection between 
HSP90 and SMYD3 offers a unique opportunity for insight into oncogenesis and possibly 
evolution. Since most cancerous cells are in a perpetually stressed state, teetering on the 
brink of apoptosis, they face continual selection pressure, much like evolving organisms 
do. Activation of epigenetic stress response pathways should permit those cells to access 
survival mechanisms that might not otherwise be accessible under lower stress 
conditions. Generically, oncogenesis and metastasis require the manipulation of several 




expression/repression of cell adhesion and motility factors, and recruitment of angiogenic 
factors. The scope of this process is analogous to measures that are required for re-
setting a differentiated cell to a state of pluripotency, followed by selection of another 
differentiated state, and favors the conditions required for rapid mutagenesis and micro-
evolution. HSP90, also termed the ‘cancer chaperone’, has a central role in these 
processes by maintaining the stability and activity of many client proteins which are 
essential for each process [13]. SMYD3 appears to place suppressive marks in normal 
cells, but may inappropriately place activating marks on other residues over time when 
continually overexpressed. This role reversal may occur because, even though SMYD3 
has greater affinity for the H3-K4 site than for other histone peptide sequences, the 
specificity of its MYND domain partners prevent it from interacting significantly with those 
sites in normal cells. Overexpression may lead to saturation of those partner binding sites 
which would then permit SMYD3 recognition of these alternate high affinity sites. HSP90 
putatively helps stabilize, localize, and activate the excess SMYD3, allowing continuous 
methylation of its targets. Such expression levels would be permanently achieved by the 
types of malignancy-associated SMYD3 promoter polymorphisms previously observed 
[11, 12, 45], leading to rapidly proliferative clonal expansion well beyond what we 
observed in our data of Figure 16. Clearly, the ability to prevent reversion to a more 
pluripotent state in the first place may suffice to significantly reduce the short term threat 
from cancers, suggesting the interaction between HSP90 and epigenetic proteins such 










Hematopoiesis is the pathway of cellular development that produces all of the cells 
that circulate in the blood [88, 96]. These cells include red blood cells and platelets in 
addition to immune cells such as macrophages, B cells and T cells. The process of 
hematopoiesis starts with a pluripotent, self-renewing hematopoietic stem cell (HSC). The 
HSC differentiates into early progenitor cells, which will develop into one of two distinct 
lineages, the myeloid and the lymphoid lines. These two lineages have committed 
precursors which further generate the multiple cells in the HSC pathway. Hematopoiesis 
occurs in the adult bone marrow and is triggered by a series of signals transported through 
the stromal environment. Many cells in this pathway undergo maturation via a progression 
of stages and selection. Aberrations in the hematopoietic cells result in a multitude of 
leukemias and lymphomas defined and named by the cell in which the transformation 
occurred (Figure 18).  Many of these cellular transformations possess chromosomal 
translocations which cause activation through transgene expression. 
Chromosomal rearrangements generally occur a specific stage in somatic cell 
types. These cells, such as those in hematopoiesis and during gametogenesis, undergo 
rearrangements in order to generate diversity. This process, though, can result in 
mutations as there is an exchange of genetic material between two non-homologous 
chromosomes. Each chromosome would have undergone double stranded DNA breaks 
through genetic instability or enzymatic activity. The exchange and joining of the double 




chromosomes called a translocation (Figure 17). One or more oncogenic translocations 
are found in most cancers.  
 In hematopoietic malignancies, there are several well studied oncogenic 
translocations. The Philadelphia chromosome, a translocation between chromosomes 9 
and 22, causes the production of a fusion genes known as BCR-Abl. This transgene 
remains constitutively active as a kinase, inducing cell signaling, deregulating 
proliferation, and prevention of apoptosis. The Philadelphia chromosome, or t(9:22), is 
present in 95% of chronic myeloid leukemia (CML) incidents. 
 Current treatment options include a hematopoietic stem cell transplant to 
repopulate healthy, non-transformed cells in addition to a drug Imatinib by Gleevec, that 
inhibits the kinase activity of the transgene. Unfortunately, compatible bone marrow 
donors are not always available and the effect of the drug is short lived.  
 Translocations involving the mixed lineage leukemia gene are also present in the 
hematopoietic pathway. Much like the SMYD proteins, the MLL gene produces a protein 
that methylates H3-K4. MLL fusion proteins have demonstrated the ability to transform 
hematopoietic cells into leukemic stem cells.     
Here we turn our attention to SMYD2 and its putative role in hematopoietic 
carcinogenesis. In order to study the effect of SMYD2 in tumor initiation, we employed 
transforming oncogenes to study the consequences of SMYD2 loss in three 
hematopoietic models: B-Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia 
(CML), and Mixed Lineage Leukemia (MLL). Loss of SMYD2 in CML and MLL, but not in 
B-ALL, models led to cell cycle block following by rampant apoptosis and cell death. 




transformation, was dependent upon SMYD2. Gene expression analyses indicated that, 
as previously determined in multiple studies, impairment included reduction in the level 
of the p53 tumor suppressor. Collectively, these studies establish SMYD2 as a putative 



















Figure 17: The Philadelphia Chromosome. A depiction of the translocation between 
chromosomes 9 and 22 resulting in the fusion gene Bcr-Abl also known as the 






Figure 18: Points of transformation in various hematopoietic derived malignancies. 
An illustration of select cells in the hematopoietic pathways during maturation and 
associated tumorigenic states.  Some of these cancer phenotypes are   also connected 





Figure 19: Cell death in HSC tumor models of CML, MLL and ALL when SMYD2 is 
deleted. Deletion of SMYD2 in MLL and CML cells reduced their viability to 30% on day 
47 (MLL) and to 16% on day 29 (CML). The viability of ALL cells, upon SMYD2 deletion, 
was comparable to the control cells. CML SMYD2 cKO cells have a higher percentage of 
about 80% of pre-apoptotic cells (Annexin V+, DAPI-), while MLL and ALL cells showed 






Figure 20: The effect of SMYD2 deletion on cell cycle protein expression and 
phases in tumor models. Cell-cycle proteins such as p53, p21, Arf and p27 showed no 
significant changes after the deletion of SMYD2 in the (A) CML, (B) MLL and (C) ALL in 
vitro tumor models. A measurement of 5-ethynyl-2-deoxyuridine (EdU) incorporation by 
flow cytometry was conducted. CML cells showed a severe block in their cell cycle where 
an increased percentage of cells were present in G0-G1 phase (about 13% more in CML 
and 9% more in MLL), accompanied with a reduction in the percentage of cells entering 
the S phase (82% less in CML and about 33% less in MLL) in comparison to the control. 
ALL cells also showed an increase in their G0-G1 phase of about 31% and a decrease in 
their S phase of about 31%.  
 
  





Figure 21: Colony formation reduced in SMYD2 depleted tumor models. After 21 
days, in case of (A) CML and (B) MPP cells, or 14 days, in case of (C) ALL cells, CML 
cells transduced with SMYD2 cKO showed a complete absence of colonies, while MPP 
and ALL cells transduced SMYD2 cKO showed a reduction in their number of colonies of 
about 85% and 35% respectively.  






Figure 22: CML-like SMYD2 deleted cells did not result in tumors. (A) In comparison 
to the control group, SMYD2 cKO-transduced CML cells failed to recapitulate leukemia in 
the recipient NOD-SCID mice. For tumor formation, 103, 104, 105 or 106 of non-treated 
(control) cre-ERT2 (n=65) or cre-ERT2 treated with 4-OHT to initiate deletion of SMYD2 
(n= 60) cells were injected intrafemorally into 6 to 8-week old male NOD/SCID mice. 
Tumor size was measured by caliper weekly for at least 3 months or until the presence 
of a tumor diameter >17mm, tumor ulceration or bleeding, when in those cases mice were 
sacrificed earlier. For examining tumor growth and/or detecting metastasis by 
bioluminescence imaging, mice were injected with luciferin. The in vivo bioluminescense 
monitoring was performed in a Xenogen IVIS Lumina II System. (B) Is a graphical 
representation of the survival rate of CML mice injected with 106 cells from (A). SMYD2 



















I conclude that SMYD2 contributes to cellular proliferation in hematopoietic 
malignancies. This was most evident with the absence of SMYD2 in the CML model which 
impacted cell viability, colony production and tumor formation. These findings support 
SMYD2 inhibition as a therapeutic means to treating HSC derived cancers. SMYD2 may 
also be a factor and potential target in the ALL pathway given that colony formation was 
decreased and the cell cycle was altered. Expression of cell cycle proteins p21 and p19 
were affected by the deletion of SMYD2 further supporting its interaction in the p53 
pathway. Continued research on the proliferation driving potential of SMYD2 in HSC 













The SMYDs have demonstrated their propensity for both cellular development and 
proliferation. When overexpressed, both SMYD2 and SMYD3 have shown to induce 
tumorigenesis [50, 101, 134-138]. SMYD2, the least characterized of the SMYDs, has 
been directly linked to immunological tumors when overexpressed and an indicator of 
poor overall survival [139, 140]. While the localization of SMYD2 in cardiomyocytes is well 
established, a conditional knockout of SMYD2 showed that it was dispensable for proper 
embryonic development of the heart [69]. SMYD2 does however methylate two well-
known tumor suppressors, p53 [67, 141] and RB1 [65, 66] by which it may regulate 
cellular proliferation in other systems. Immunological cancers stem from a single 
pluripotent stem cell, the hematopoietic stem cell (HSC) [88]. From the HSC, all cells that 
circulate within the bloodstream are produced, including red blood cells, B cells, T cells, 
macrophages and monocytes.  
Here we report our efforts to extend the above findings to the living organism. 
SMYD2 was conditionally deleted via cre/Lox methodology from the germline of C57BL.6 
mice exclusively in hematopoietic progenitors. SMYD2-deficient mice were born healthy 
and achieved normal lifespans. However, consistent with our findings of Chapter 4, we 
observed significant blocks in the progression of fetal and bone marrow hematopoietic 
stem cells to both B lymphocoyte and myeloid lineages. While these blocks led to an 
overall reduction of mature peripheral B cells. These studies further support a model in 





A. RESULTS  
Loss of SMYD2 reduces HSCs  
The overall expression of SMYD2 throughout hematopoiesis indicates its potential 
importance for normal development in the pathway (Figure 9). To determine the effect of 
HSCs and early progenitors, a conditional knock out of SMYD2 was generated in a murine 
model. Both an embryonic (vav cKO) and an adult inducible (mx1 cKO) cre-mediated 
HSC specific promoter were used to delete SMYD2. These cells also possessed an 
inducible YFP marker to indicate when SMYD2 was deleted.  
The vav deletion of SMYD2 at the HSC did not prove to be fatal. cKO mice 
appeared to be as healthy and the same size as control mice and did not encounter a 
higher disease burden or rate of mortality in comparison to control mice. Litter sizes were 
average for all mice and the gender distributions were in line with the controls as well. 
Upon closer inspection of cell populations via flow cytometry, cKO mice did exhibit a 
depletion of a small subset of the bone marrow hematopoietic stem cell population 
(Figure 23). Despite the loss of this population, the HSCs progressed into the next cell 
stage to the multipotent progenitor (MPP). The vav cKO resulted in increased MPPs 
contrary to the mx1 cKO which saw a decrease in those cells. In, the following stage, the 
lymphoid multipotent progenitor (LMPP), in both models was significantly affected. Again 
the two deletion models showed opposite trends with the embryonic deletion resulting in 
increased LMPPs and the mx1 deletion causing a reduction in the LMPP population. The 
deletion of SMYD2 shows an early block in hematopoietic stem cells and it may prove to 




look for perturbations in regard to an expansion or depletion of cell proliferation measured 
by flow cytometry.  
 
SMYD2 increases the population of myeloid and lymphoid progenitors 
Downstream of the earliest progenitors, the pathway diverges into one of two very well 
defined lineages, the myeloid or the lymphoid lines [142]. Each of these are characterized 
by a committed precursor, either the common myeloid progenitor (CMP) or the common 
lymphoid progenitor (CLP) [143]. To determine if SMYD2 had a greater impact beyond 
the HSC, analysis was continued to investigate which committed lineage was the most 
dependent on SMYD2. Based on the expression of SMYD2 in hematopoiesis (Figure 9), 
we reasoned that the myeloid lineage was likely to be affected.   
 The committed progenitors of the myeloid and lymphoid branches, CMP and CLP, 
respectively, further differentiate to ultimately populate and produce a multitude of mature 
cells (Figure 6). In the vav cKO model, CMPs and CLPs were significantly increased 
whereas in the mx1 cKO, the CLPs were significantly decreased and the CMPs were 
modestly decreased (Figure 24). The loss of SMYD2 in the vav cKO suggests that further 
blocks exist downstream of these cells in both lineages while the mx1 deletion suggests 
that only lymphocytes would be affected.  
 
SMYD2 deficient CMPs and CLPs contribute to increased pDCs  
Previously shown in figure 24, the SMYD2 vav cKO resulted in increased 
populations of both CMPs and CLPs. This is may prove significant in regard to 




Dendritic cells, in general, are responsible for taking up antigen circulating in the 
bloodstream and presenting them to T and B cells in order to illicit an immune response 
[145, 146]. Their unique shape, upon activation, creates a net type effect to capture 
antigen as well as to maintain contact and adhesion with T and B cells. Dendritic cells are 
also highly motile surveying the blood and migrating to locations of concentrated T or B 
cells primed for activation.  There are several subtypes of these antigen presenting cells 
and we focused primarily at the pDC. The pDCs tend to be associated with lymphocytes 
based on their resident localization and B cell lineage (B220+) marker [144, 147, 148]. To 
determine if the resulting increase in both the CMP and the CLP also affected pDCs, flow 
cytometry was used to investigate the effect on pDCs from both the bone marrow and 
spleen.  
Considering the impact pDCs have in the immune system, their increase could 
skew the ability of the cells to properly react to antigen. pDCs produce type I interferons 
(IFNs) which at basal levels help to initiate the immune response. However, higher 
concentrations of IFN can result in immunosuppression and reduce further signaling. 
Consequently, the T and B cells, which directly interact with pDCs may be impacted with 
regard to population size and/or function. Our experiments showed that pDCs were 
indeed increased in both cKO models (Figure 25).  
 
mx1 cKO reduces T cell populations 
The gene expression data indicated high expression of SMYD2 through most of T 
cell differentiation (Figure 9). While SMYD2 did not prove to be vital for T cell development 




decreased by the mx1 SMYD2 deletion. Decreased levels of CD4+ T cells have been 
associated with CML [149, 150].  
 
B cell progenitors most affected by SMYD2 depletion 
B cells mature from a pre-progenitor-B cell through a series of intermediate states until 
they finally mature and are subsequently activated to antibody secreting plasma cells 
(Figure 27) [151-153]. B cell development starts just downstream of the CLP. From here 
the lineage begins with a pre-progenitor B cell (pre-pro B), also known as Hardy’s fraction 
A [154]. This cell continues to mature in a linear progression accumulating different cell 
surface markers as the (v)ariable, (d)iversity, and (j)oining gene (VDJ) chain 
rearrangement occurs [155]. B220+ is the indicator for any dedicated B cell and is 
expressed from the progenitor B (pro B) cell or Hardy’s fraction B and onward. The pro B 
will eventually enter into the stage of the large pre B where VDJ rearrangement has halted 
and it begins actively dividing and proliferating. The divided large pre B cell gives rise to 
smaller nonproliferaing small pre B cells which ultimately produce the immature B cell 
(imm B).  
The expression data (Figure 9) indicated that SMYD2 was only present very early 
in B cell development. Therefore, the deletion of SMYD2 was not expected to have a 
severe impact on B cells beyond their earliest stages. However, in both the vav and mx1 
cKOs, the loss of SMYD2 greatly affected B cell progenitors with the mx1 deletion causing 
a dramatic loss of cells contrary to an increase in the vav deleted cells (Figure 28). 
Beyond pro-B cells, the vav cKO cells were not further impacted. In contrast, mx1 cre 




associated with the site of transformation for pre B-ALL. This suggests a potential role for 
SMYD2 in both early B cell development and the initiation of ALL. 
As B cells continue to mature, a vast majority can be found in various splenic 
localizations. Follicular B cells make up follicles of B cells in the white pulp of the spleen. 
These cells are primed and organized around dendritic cells for fast activation. Marginal 
zone B cells reside in the red pulp region of the spleen and do not circulate. These cells 
are also primed to be recruited to assist in immunity by T cell activation. Marginal zone 
cells more rapidly differentiate to plasma cells. In these mature cells the deletion of 
SMYD2 facilitated by vav versus mx1 resulted in differing outcomes. The mx1 deletion 
continued its trend of depleted populations from immature spleen cells through 
transitional 1 B cells. However, the vav deletion resulted in only modest increases of cells 
in the mature, follicular and marginal zone B cells (Figure 29).  
To test the functionality of mature cells, a B cell specific SMYD2 cKO was 
generated using mb1 cre. The use of this cre results in the deletion of SMYD2 prior to the 
pre-B cell. For specific function of B cells devoid of SMYD2, we immunized mb1 cKO and 
control mice. Their blood sera were analyzed over time to determine if the absence of 
SMYD2 had an effect on the antibody repertoire produced. IgM, IgA and IgG isotypes 








Figure 23: SMYD deficiency results in loss of HSC population in vav and adult cells. 
(A) Flow cytometric scatter plots of fetal and adult bone marrow. HSC populations from 
fetal livers were relatively normal (B) A graphical representation of cell numbers from 
adult bone marrow. Both the vav and mx1 SMYD2 deletions exhibited a loss of a smaller 
HSC population. In the mx1 cKO model, early cell populations continued a trend of 
decline. This culminated to a significant decrease of LMPPs. However, in the vav deletion, 







population. HSC, MPPs and LMPPs share similar transmembrane receptor expression in 
that they are all lineage negative, Sca-1+ and c-kit high. However, they have varying 
expression of Flt3 with HSC expressing none, MPPs exhibiting an intermediate level of 
expression and LMPPs with high expression of Flt3. (C) Illustrates the early stages of 
differentiation of the HSC towards a committed lineage progenitor. The total number of 
cells was determined by: [(total number of femur/spleen/thymus cells harvested/# of cells 














Figure 24: Depletion of SMYD2 affects early lineage progenitors. (A) Scatter plots 
and (B) graphical representations indicated that both the myeloid (CMP) and the lymphoid 
(CLP) committed progenitors were affected by the loss of SMYD2. The vav cre exhibited 
drastic increases in both cell types while mx1 cre demonstrated decreased populations, 
particularly in the CLPs.  
Vav cKO 
mx1 cKO 
Controls cKO Controls cKO 







Figure 25: Increase of plasmacytoid dendritic cells (pDCs) in SMYD2 deletion. The 





















Figure 26: Thymic T-cell populations are only impacted in mx1 cKO.  SMYD2 did not 
prove to be vital for T cell development in the vav cKO. Two of the T cell populations were 
affected by the mx1 SMYD2 deletion. The immature double negative and the CD4+ cells 










Figure 27: Linear development of B cells. (A) B cells mature from a B cell progenitor 
downstream of the CLP known as the pre-progenitor B cell. After this stage they express 
B220+, the lineage marker for B cells. B cells enter a proliferative state at the Large pre-
B cell and arrest division at the small pre-B stage. Immature B cells migrate out of the 
bone marrow to other resident organs including the spleen where maturation continues. 
Mature B cells circulate through the bloodstream and differentiate into plasma cells if 
activated by antigen. Plasma cells secrete one type of antibody and aid in the adaptive 
immune response.  (B) Cell marker expression varies throughout B cell maturation. Cells 














































Figure 28:  Bone marrow B cell development in the absence of SMYD2.  The vav 
ckO exhibited modest increases of each bone marrow B cell population resulting in an 
overall significant increase in the total immature bone marrow B cells. The mx1 cKO, 
however, severely decreased overall immature, and pre-B cells, specifically affecting the 
small pre B cells. The small pre-B stage is associated with the site of transformation for 
B-ALL.  





Figure 29: The effect of SMYD2 deletion in mature splenic B cell populations. (A) A 
scatter plot showing the shift of mature spleen cells to the follicular and marginal zone B 
cell populations in the mx1 cre. (B) Only the mx1 deletion of SMYD2 showed significant 
changes in the mature B cells. Overall splenic B cells were reduced from immature 
through transitional 1 B cells. The vav deletion resulted in modest increases of cells in the 
mature, follicular and marginal zone B cells. * statistical significance p=<0.005 
A. 
B. 





Figure 30: Antibody response in B cell specific (mb1) deletion of SMYD2. Analysis 
of the antibody production and response to immunization showed little difference between 
SMYD2 B cell deleted cells and control cells. While the response was robust in both 







I conclude that SMYD2 is required for proper hematopoietic development. The 
initial loss of a small HSC population was evident in both deletion models. Aberrations 
continued in the pathway, of note, in the committed progenitors of both the myeloid and 
lymphoid lineages. I further propose that SMYD2 plays a role in lymphocyte development. 










The ultimate goal of this research was to better understand the function of SMYD2 
and SMYD3. Analysis of the SMYD3 structure (Figure 10) revealed that a relatively large 
space near the post-SET domain and N-terminal portion of the CTD along the inner wall 
of the pocket is decorated by polar residues from the CTD (mainly residues from N324-
C333 of helix 4) (Figure 11). Conserved clustering suggests that these polar residues 
might cooperate with the post-SET residues to restrict the histone substrate on both sides 
of the methyl-lysine. In this context, the CTD could function as a cap necessary to bind 
substrates effectively and selectively. Consistent with this hypothesis, deletion of CTD 
helices 1–9 [SMYD3(1–279)] eliminated basal HMTase activity of SMYD3 for histone H4 
(Figure 12A). 
Further investigation of the unanticipated role of the SMYD family’s TPR-like CTD in 
intra-nuclear trafficking may provide insight into the potential for more specific localization 
of proteins regulated by the TPR-HSP90 interface. Experiments involving HSP90 
chaperone inhibitors, such as geldanamycin, together with cells expressing either WT or 
mutant SMYD3 proteins, might lead to a better understanding of the interplay between 
these proteins. Significant research, however, still remains in order to fully delineate the 
influence of HSP90 conformation and activation state on the ability of its C-terminus to 
interact with TPR and TPR-like motifs, as well as its ability to influence cell localization 
and nuclear trafficking. Additional experiments which isolate the nuclear localization 




The CTD mediated stability of the SMYD3 active site also implies that the CTD is a 
potential pharmacologic target for the selective knockdown of SMYD3. Most HMTases 
share a sizable affinity for the methyl donor, S-adenosyl-methionine (SAM), making such 
a site less desirable as a drug target. Small molecule inhibitors which target the substrate 
binding site of other HMTases have achieved reasonable potencies and selectivities 
against those HMTases [46, 47]. That even the most distal portions of the CTD are 
necessary for basal function, despite predictions of less direct involvement in substrate 
binding, implies a non-competitive, allosteric means to regulate SMYD3 activity.  
The cooperation between HSP90 and SMYDs in oncogenesis presents a novel 
direction for the clinical management of the resulting malignancies from an HSP90 
perspective as well. If its association with SMYD3 is a primary driver of its oncogenic 
potential, blocking that association could have positive clinical outcomes. HSP90 has 
been the target of many novel cancer therapeutics which eliminate its chaperone function. 
Unfortunately, unintended consequences of eliminating the chaperone activity of this 
broadly expressed protein include off-target toxicities, such as a variety of gastrointestinal 
side effects [48]. The development of a drug which blocks HSP90-SMYD3 interactions 
via binding the CTD of SMYD3 may remove transformative avenues of HSP90-driven 
malignancy without inducing the unintended side effects associated with broad spectrum 
HSP90 chaperone inhibition. This would still allow basal signaling of SMYD3 in the 
cytoplasm, thus affecting its nuclear signaling selectively. To ascertain the utility of this 
approach, development of probe compounds which target SMYD3 and specifically 




Analysis of SMYD2 via three in vitro hematopoietic malignant models underscored 
its potential role in oncogenesis. Further studies of these tumors and examination of 
tumor suppressor methylation may elucidate the mechanisms by which SMYD2 affects 
proliferation. SMYD2 is known to methylate residue K370 of p53 hindering its function of 
mediating apoptosis. The absence of SMYD2 in the cre mediated deletions and the 
resulting cell death further imply that SMYD2 plays a potential regulatory role of p53. The 
presence of the constitutively active tyrosine kinase, bcr-abl, may enhance SMYD2 
repression of p53 even when not overexpressed. Future experiments analyzing 
methylation, gene expression and cell viability with an overexpression of SMYD2 in the 
presence of the transgene will be informative. In addition, in vivo overexpression and 
induced cKO studies without bcr-abl would reveal if inhibition of SMYD2 alone is sufficient 
to reduce and eliminate HSC tumors.  
 Considering that much like SMYD3, SMYD2 activity can be enhanced by HSP90 
interactions [85, 156, 157], investigating this too in our tumor models would be of value. 
The bcr-abl construct may heighten the ability of HSP90 to bind to SMYD2 and thereby 
increase its methylation activity. Experiments aimed toward determining SMYD2 
methylation in a system with and without both bcr-abl and HSP90 could prove to be of 
merit with regard to therapeutic development. Although, as previously mentioned, since 
targeting HSP90 results in unintended consequences, understanding the many potential 
mechanisms that contribute to SMYD2 activity is important to its targeted inhibition.    
 Utilizing our vav and mx1 cre SMYD2 deletion models, we sought to determine the 
overall role of SMYD2 in hematopoiesis, ultimately investigating potential sites of tumor 




population. Thus, SMYD2 may be a factor in stromal signaling that drives HSC 
differentiation. Further analysis of the variations in cell populations in a SMYD2 
overexpression model would be especially telling if the depleted population remained 
and/or increased. In addition, isolating the HSC and conducting cell cycle analysis would 
determine if the population lost was of a proliferating or senescent nature. Every 
aberration observed downstream was likely linked to this initial depleted population of 
cells.  
B cell progenitors were altered due to the deletion of SMYD2. Many lymphomas 
and leukemias are directly associated with transformations during B cell development and 
SMYD2 may contribute to those. Although progenitor B cells were affected by the loss of 
SMYD2, mature B cells exhibited a normal response when stimulated. Considering the 
known SMYD2 interactions with tumor suppressors p53 and RB1, its role may be better 
revealed if the system was subject to stressors. DNA damage would provide insight to 
the potential regulation of p53 and RB1 by SMYD2. Hypoxic, heat and toxic stressors 
would not only allow analysis of tumor suppressors but also of chaperone proteins 
expressed under these conditions. Observing these in both an overexpression and 
knockout model could reveal a clearer picture of the role of SMYD2 in these regulatory 
pathways.  
At the onset of this study, we were unsure if we could trigger the deletion of SMYD2 
in vitro via our mx1 cre constructs. The in vivo, mx1 cre requires multiple injections of a 
double stranded RNA mimic, PI:PC, which induces an interferon response ultimately 
activating the cre-recombinase. In vitro, were unsure of how to deliver a proper dosage 




OP-9 cells and cytokines, we cultured bone marrow cells toward the B cell lineage and 
were able to maintain cell viability and effectively knockout SMYD2 (Figure 31). This 
approach could be used to subject cancer cell models to stress both before and after 







Figure 31. In vitro deletion of SMYD2 with mx1 cre. Mx1 cre bone marrow cells were 
plated on a co-culture of OP-9 cells with cytokines. PI:PC was either, (A) not administered 
(NO PIPC), (B) administered in the same time frame as in vivo, once every other day for 
five days (1 x 5) or (C) all at once in one day (5 x 1). Cells were harvested and analyzed 
by flow cytometry at day 10. Row 1 exhibits the size and granularity of the total cell 
composition with forward scatter plotted against side scatter. The scatter plots in row 2 
show that the slower administration over several days yielded the highest deletion of 
SMYD2 indicated by presence of YFP (B. Row 2). 83% of cells expressed YFP in the (B) 
1 x 5 dosing versus 25% in (C. Row 2) the 5 x 1 dose. Cells progressed towards early 
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ABBREVIATION MEANING PAGE 
AGM Aorta, gonad, mesonephros 9 
ALL Acute lymphoblastic leukemia  11 
BLP B cell lineage progenitor 20 
CD Cluster of differentiation 20 
CD4+ CD69- (referring to cell markers on T cells) 20 
CD4+ CD69+ (referring to cell markers on T cells) 20 
CD8+ CD69- (referring to cell markers on T cells) 20 
CD8+ CD69+ (referring to cell markers on T cells) 20 
cKO Conditional knockout  14 
CLP Common lymphoid progenitor 12 
CML Chronic myeloid leukemia 12 
CMP Common myeloid progenitor 12 
DN1 Double negative 1 (referring to T cells) 20 
DN3 Double negative 3 (referring to T cells) 20 
DN4 Double negative 4 (referring to T cells) 20 
DP CD69- Double positive (referring to T cells) 20 
DP CD69+ Double positive (referring to T cells) 20 
EP Erythroid progenitor 20 
Ery Erythrocyte 20 
Flt3 fms-like tyrosine kinase 3 10 
Fo B Follicular B cell 20 
gGMP Pre granulocyte/macrophage progenitor 20 
GMLP Granulocyte/macrophage-lymphoid progenitor  10 
GMP Granulocyte/macrophage progenitor 20 
GRAN Granulocytes 20 
H(x)-K(x) Histone(x)-Lysine(x) 3 
HAT Histone acetyltransferase 9 
HDAC Histone deacetyltransferase 2 
HKMT Histone lysine methyltransferase 2 
HMTases Histone methyltransferases  40 
HSC Hematopoietic stem cell 9 
IFN Interferon 78 
IL-3 Interleukin 3 10 
IL-7 Interleukin 7 10 
Imm B Immature B cell 20 
iNK Natural Killer 20 
LMPP Lymphoid primed multipotent progenitor  10 




ABBREVIATION MEANING PAGE 
LSD1 Lysine demethylase 3 
MACRO Macrophage 20 
Mat B Mature B cell 20 
Me 1/2/3 Mono/di/tri methylation 3 
Megak Megakaryocyte 20 
MEP Megakaryocyte/erythroid progenitor 10 
MKP Megakaryocyte progenitor 20 
MLL Mixed lineage leukemia 66 
mNK Natural Killer 20 
MONO Monocytes 20 
MP  Monocyte progenitor 20 
MPP Multipotent progenitor  10 
MT Methyltransferase 3 
MYND Myeloid-Nervy-DEAF1 4 
Mz B Marginal zone B cell 20 
New B Immature B cell 20 
pCFU Pre colony forming units 20 
PCR Polymerase chain reaction 24 
pDC Plasmacytoid dendritic cell  77 
Plt Platelets 20 
pMEP Pre megakaryocyte/erythroid progenitor 20 
Pre-B  Pre B cell   10 
Pre-B-ALL Pre B cell acute lymphoblastic leukemia 11 
Pre-pro B Pre progenitor B cell 11 
Pro-B Progenitor B cell 19 
RB1 Retinoblastoma 6 
RBC Red blood cells 9 
SAM S-adenylsylmethionine 4 
sCMP Common myeloid progenitor 11 
SET Suppressor of variegation, enhancer of zeste and trithorax  4 
skNAC Skeletal nascent polypeptide-associated complex alpha 5 
SMYD SET and MYND domain containing protein 4 
T1 B Transitional B cell 1 20 
T2 B Transitional B cell 2 20 
TPR Tetratricopeptide repeat 8 
VDJ Variable, diversity, and joining genes 79 
   
   
 
